Cannabis & Cannabinoids · Cannabinoids · Minor cannabinoid; a THC look-alike with a shorter side chain; effects depend on the amount

THCV (Tetrahydrocannabivarin)

Q: Is THCV the same as THC?

No. A 2025 perspective says THCV is not an isomer of THC, is made by the plant from a different starting acid, and cannot be converted to or from THC by any known reaction. They share a ring structure but THCV has a three-carbon side chain, and in most studies it blocks the CB1 receptor that THC activates.

Q: Does THCV get you high?

It depends on the amount and the form. About 10 mg of delta-9-THCV could not be told from placebo in small studies. At 100 and 200 mg of the man-made delta-8 form, volunteers rated feeling and liking a drug effect, and euphoric mood was the most common mild side effect. No study tested delta-9-THCV at higher amounts. Products labelled THCV may also hold THC.

Q: Does THCV help with weight loss?

The evidence is thin. The only human weight result is from a 90-day study of mouth strips that combined THCV with CBD, whose abstract has no numbers. In mice, pure THCV cut food intake in one study and did not in another. Two brain-scan studies found no change in ratings of food. The "diet weed" nickname is ahead of the evidence.

Q: Does THCV help with type 2 diabetes?

One 13-week trial in 62 adults found THCV alone lowered fasting blood sugar compared with placebo, but it missed its main target (HDL cholesterol), used many secondary measures and has not been repeated. A doctor treats diabetes; do not stop or change medicine because of this.

Q: Can THCV block the effects of THC?

Partly, in one tiny pilot. In 10 men, five days of THCV cut the THC rise in heart rate and made THC feel weaker, but increased memory intrusions. THC was given by vein at a small amount. In rats, THCV blocked or mimicked THC depending on the amount. It should not be used to offset cannabis.

Q: What is the difference between delta-9 and delta-8 THCV?

Delta-9-THCV is the plant form. A review says delta-8-THCV has not been reported in cannabis plants and is probably semi-synthetic, made from CBDV. The highest-amount human trial used delta-8. The isomers differ in lab potency, and a labelled "THCV" product may be either.

Q: What are the side effects, and can I drive?

In short trials, side effects were mostly mild. Euphoric mood was the most common in the delta-8 trial, and the diabetes trial said THCV was well tolerated. Long-term effects are unknown. Driving was not tested, and higher amounts felt like a drug, so do not drive if you feel impaired.

Q: Will THCV show up on a drug test?

It can. After delta-8-THCV, 78 of 79 urine screens were positive for THC in one report, and 70 of 80 samples read positive on a THC screen in another though confirmation tests were negative for THC. Half of 117 patients in a different study had no detectable THCV metabolite after smoking cannabis, so THCV testing is not a reliable marker either way.

Q: Do THCV products contain what the label says?

We found no study that tested THCV-labelled products. Tests of CBD products show minor cannabinoids are often missing from labels, and a review says labels rarely say whether THCV is the delta-9 or delta-8 form. A batch certificate of analysis from an independent lab is the only way to know.

(6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol (C19H26O2; PubChem CID 93147) · also called THCV, delta-9-THCV, tetrahydrocannabivarin; nicknamed "diet weed"; its acid form is THCVA; a man-made isomer, delta-8-THCV, is also sold

THCV is a compound found in small amounts in some cannabis plants. It looks like THC but has a three-carbon side chain instead of five, and a review says it is not an isomer of THC and is not made from it. Human research is a few small studies; some key papers are tied to cannabis companies. In small studies about 10 mg could not be told from placebo, while much higher amounts of a man-made form felt like a drug. No THCV medicine is approved.

General information, not medical advice. Last substantive update October 25, 2026 · Not medically reviewed. A named clinician has not signed off on this page. How this page is made

About THCV (Tetrahydrocannabivarin)

THCV (tetrahydrocannabivarin) looks like THC but has a three-carbon side chain instead of five. A review says it is not an isomer of THC and is not made from it. Human research is a handful of small studies: a 13-week diabetes trial that missed its main target but lowered fasting blood sugar, a 10-man pilot where THCV blunted some THC effects and increased one, two brain-scan studies, and a trial of a man-made delta-8 form where higher amounts felt like a drug. Almost everything else is animal or lab work, and several key papers are tied to cannabis companies.

What THCV is, and how it differs from THC

THCV (tetrahydrocannabivarin) is a compound found in small amounts in some cannabis plants. Its formula is C19H26O2. It has the same ring structure as THC but a propyl (three-carbon) side chain where THC has a pentyl (five-carbon) chain. A 2025 perspective says THCV is not an isomer of THC, that no known plant pathway or chemical reaction turns THC into THCV, and that the plant makes it from a different starting acid.

There are two forms with the same name. Delta-9-THCV is the plant form. Delta-8-THCV has not been reported in cannabis plants; the same perspective says it is probably made in the lab from CBDV, another cannabinoid. Labels usually say only "THCV". Many human studies used one form or the other, so results from one should not be assumed for the other.

^{39 10 36 38}

What the human studies show, including the nulls

The best-known trial gave 62 adults with type 2 diabetes THCV, CBD, mixtures or placebo for 13 weeks. Its main target, HDL cholesterol, did not change. THCV alone lowered fasting blood sugar compared with placebo (a difference of about 1.2 mmol/L), but that came from many secondary measures in groups of about a dozen. The CBD and mixture groups showed no clear effect. It has not been repeated.

Two single-dose brain-scan studies in 20 healthy volunteers each found that THCV changed brain responses to food cues and resting brain connectivity, but not how people felt or rated food. A 10-man pilot found five days of THCV blunted some effects of a small intravenous THC dose and made THC feel weaker, but increased memory intrusions; THC itself caused little psychotic or memory impairment at that amount, so there was little to block. One 90-day study of mouth strips that combined THCV with CBD reported weight loss, but the abstract has no numbers and the strips held CBD too.

Several of these papers are tied to companies. The delta-8-THCV trial was funded by Canopy Growth Corporation, and several of its authors were Canopy employees at the time. Also, a 2025 perspective arguing that THCV should not be treated like THC is by authors from cannabis companies. One diabetes-trial author is listed with GW Pharmaceuticals, and the strip study author is listed with a company called NeX Therapeutics.

^{13 33 27 6 31 22 10 20}

Does it block THC or act like it? It depends on the amount

Reviews say THCV mostly blocks the CB1 receptor (the main target of THC) at the amounts in most studies, but can act as a weak agonist at higher amounts. In rats trained to recognise THC, THCV partly felt like THC at one amount (3 mg/kg) and reversed a low THC amount at a higher one (6 mg/kg). In mice, THCV did not change the THC cue.

In people, about 10 mg of delta-9-THCV by mouth was not different from placebo in small studies. In the delta-8-THCV trial, 12.5 to 50 mg did not show THC-like effects, while 100 and 200 mg raised ratings of feeling and liking a drug effect, and euphoric mood was the most common mild side effect. A review by industry authors calls these effects low in size compared with THC at under 10 mg. These are study amounts, not advice; the sources do not say what amount is safe.

^{15 41 21 19 10 6 22 30}

Animal and laboratory research is not human evidence

Many of the headline claims come from rodents and cells. THCV protected nerve cells and eased movement in Parkinson's models, reduced seizures in rats, reduced swelling and pain in mice and rats, reduced alcohol drinking in rats and lowered inflammation markers in human cells. In obese mice it improved glucose tolerance and insulin sensitivity, though it did not clearly change food intake or weight.

Animal amounts do not carry over to people, models are narrow, and many results come from one lab. None of this shows that THCV treats any condition. We rate these uses insufficient.

^{8 7 12 1 23 24 9 40 26}

Shop products, drug tests and the law

We found no test of whether products labelled THCV match their labels. Tests of CBD products show minor cannabinoids often missing from labels, and in 148 UK CBD edibles, 66% of those with measurable CBD had one or more UK-controlled cannabinoids; THCV is among those the paper measured. Online retailers have described THCV among products "suitable for new users". In one trial, delta-9-THCV showed up in blood even though the delta-8 product was said not to contain it.

After active delta-8-THCV doses, most urine screens were positive for THC even when the confirmation test was negative for THC, so a THCV product may cause a failed drug test. The US FDA has approved no THCV medicine and does not mention THCV on its cannabis Q&A page. US federal hemp rules are changing, with most parts due December 11, 2026; the summary we read does not name THCV. In the United Kingdom, the Misuse of Drugs Act lists cannabinol derivatives in Class B but does not name THCV, and a 2025 laboratory paper calls THCV a UK controlled cannabinoid. Rules differ by place; this is not legal advice.

^{14 11 18 28 22 29 17 35 3 34}

What the lab numbers show

Our data holds 101 laboratory measurements of THCV in cannabis flower for 83 differently named strains. They come from published papers; we did not test anything ourselves. A strain name is only a label: the same name can have very different chemistry, and these are real results from specific samples.

The biggest group is 30 values for 30 names from a published dataset of greenhouse-grown plants, listed as percent of flower dry weight (means of 3 to 9 plants per name; the exact counts are not in the table). Values run from 0.02 to 1.3, with a median of 0.085. Only three names reach 0.5 or more: Platinum Buffalo (1.3), Platinum Scout (1.01) and Crystal Cookies (0.97). The lowest are Bohdi Tree, Juanita and Sour Willie, each at 0.02. Of our profile strains, Blue Dream is 0.03 and White Widow is 0.05 in this group.

Other sources use other units and methods, so do not compare them with that group. One paper lists 62 single commercial batches for 52 names (0.000132 to 0.0111), printed under a "% dry wt" column although the size looks like a fraction, so the unit is not verified; Chemdawg appears only there. Another gives four plant lines at 0.05 to 0.24 percent w/w (means of two readings from 1 to 3 plants each; Malawi x Super Skunk 0.24 from one plant, Pot of Gold 0.08, Pot of Gold nr. 11 0.07, Wappa 0.05). A further table gives delta-9-THCV for five names, with values that match the main group.

The same line can change by sample: Green Crack is 0.16 and a 2015 Green Crack sample is 0.12, and Lavendar Jones is 0.09 against 0.10 in 2015. In plain terms, most flower here holds very little THCV and a few plant lines hold much more. These numbers describe how much THCV the flower held when it was tested. They say nothing about how it will feel, and nothing about THCV gummies, vapes or oils.

At a glance

Traditional uses history, not proof

Cannabis has a long history of use as a whole plant. No traditional use of isolated THCV is described in the sources read; this page covers only the compound. A 2025 perspective says delta-9-THCV was first discovered in the cannabis plant in 1971 (not independently checked).

Studied for research

Type 2 diabetes, blood sugar (one small 13-week trial): very low
Weight and appetite: insufficient
Brain responses to food cues (brain scans in healthy volunteers): insufficient
Blunting some effects of THC (10-man pilot): very low
Whether it is intoxicating, by amount: low
Parkinson's disease, seizures, pain, inflammation, alcohol drinking, mental health (animal or lab research): insufficient

Main compounds

Delta-9-THCV (the plant form)
Delta-8-THCV (a man-made isomer)
THCVA, the acid form made by the plant
THC and CBDV, related molecules it is often confused with or made from

Common forms

Pure THCV in capsules or oil (used in trials)
THCV plus CBD in mouth strips (used in one trial)
THCV-rich cannabis extracts and flower (a small share of the plant)
Hemp-derived THCV gummies, vapes and oils (not approved medicines; contents untested in the sources read)

Research links: FDA: cannabis and CBD questions and answers (does not mention THCV) · PubMed: THCV and CBD in type 2 diabetes, 13-week randomized trial (2016) · PubMed: five-day THCV before THC in healthy volunteers, pilot trial (2016) · PubMed: oral delta-8-THCV, dose-ranging placebo-controlled study (2023) · PubMed: Tetrahydrocannabivarin is not tetrahydrocannabinol (perspective, 2025) · PubChem: tetrahydrocannabivarin · Research Library · Genes & Biomarkers Library

What it is and its history

Name: Tetrahydrocannabivarin (THCV; delta-9-THCV)
Chemical name: (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Other names: Tetrahydrocannabivarin; delta9-Tetrahydrocannabivarin; THCV; THC-V; Delta9-THCV; delta9-Tetrahydrocannabivarol; GWP42004; CAS 31262-37-0; PubChem CID 93147
Common names: THCV (English); Tetrahydrocannabivarin (English); "Diet weed" (English (popular nickname for THCV, not a scientific name))
Formula: C19H26O2
Molecular weight: 286.4
CAS number: 31262-37-0
PubChem ID: 93147
Chemical class: Phytocannabinoid, "varin" type (a 19-carbon cannabinoid with a three-carbon propyl side chain, where THC has a five-carbon pentyl chain)
How the plant makes it: A 2025 perspective says there is no known pathway in the cannabis plant, and no chemical reaction, that turns THC into THCV or the reverse. In the plant, tetrahydrocannabivarinic acid (THCVA) comes from varinolic acid, while the acid form of THC (THCA) comes from olivetolic acid. Natural decarboxylation, which heat speeds up, turns THCVA into THCV. The same source says delta-8-THCV has not been reported in cannabis plants and is probably a semi-synthetic product made by acid isomerization of cannabidivarin (CBDV).
Where it is found: A minor cannabinoid in many cannabis plants. A review says plants dominant in THCV are rare. A 2001 clinical study used marijuana with 0.12% THCV (and 2.11% THC). Our lab data show THCV measured in 83 named strains; in the biggest group, a published dataset of greenhouse-grown plants, the values run from 0.02 to 1.3 percent of flower dry weight, with a median of 0.085.
Related or similar compounds: Name: THC (delta-9-tetrahydrocannabinol); Note: Same ring structure, but a five-carbon chain instead of three. THC is the main intoxicating compound of cannabis; at about 10 mg by mouth THCV was not distinguishable from placebo in small studies. THCV is not an isomer of THC.; Name: Delta-8-THCV; Note: A man-made isomer of THCV. It was the form given in the highest-amount human trial, and it can produce THC-like effects at 100 and 200 mg. Products labelled THCV may be this form.; Name: CBDV (cannabidivarin); Note: A different molecule with the same formula (C19H26O2); a review says it is the starting point for making delta-8-THCV.; Name: Delta-8-THC and other THC isomers; Note: Intoxicating compounds sold in hemp products; they are not THCV.

Traditional use and history history, not clinical proof

Tradition or era	Documented use	Source
1971	A 2025 perspective says delta-9-THCV was first discovered in Cannabis sativa by Merkus in 1971. We have not read the original report.	p38995871
2001	Researchers proposed THCV as a marker to tell marijuana from the prescription THC medicine Marinol, because THCV is a natural part of cannabis but is not in Marinol. In four volunteers, the urine THCV metabolite appeared after marijuana and not after Marinol.	p11599601
2008	A review of the lab literature described delta-9-THCV as a potent CB2 partial agonist in vitro that blocks cannabinoid agonists in CB1-expressing tissues, and in living animals acts as a CB1 antagonist or, at higher doses, an agonist.	p17828291
2009 to 2013	Mouse and rat studies reported THCV cut food intake in mice (2009), reduced seizures in rats (2010), reduced inflammation and pain in mice (2010), eased movement problems and protected nerve cells in Parkinson's models (2011) and improved insulin sensitivity in obese mice (2013).	p19378378
2010	A trial of dronabinol in cannabis-dependent patients found that half of 117 patients had an undetectable urine THCV metabolite, so THCV testing may not detect all marijuana use.	p19733018
2014 to 2016	The first small human studies: brain-scan studies of single 10 mg doses in healthy volunteers (2014, 2015), a 10-man pilot of THCV before THC (2016) and a 13-week trial in type 2 diabetes (2016).	p25542687
2023 to 2025	A two-part dose-ranging trial of delta-8-THCV (12.5 to 200 mg) in 21 healthy adults was published, along with pharmacokinetic and urine-test follow-ups. A perspective by authors from cannabis companies argues THCV should not be grouped with THC for regulation.	p37721990

History shows how a substance was used or discovered. It does not show that a product works or is safe today.

What is inside, and how it may work

What it contains and how those compounds act in cells and animals. Laboratory and animal mechanisms are not proven effects in people.

Main compounds

Compound	Family	Where it is concentrated	Activity studied	Level of evidence
THC (delta-9-tetrahydrocannabinol) PubChem 16078	Phytocannabinoid	Not read in the sources Not read	The best-known compound of the same shape. THC is a potent CB1 partial agonist and causes the high; THCV has a three-carbon side chain and, in most studies, blocks CB1. THCV is not made from THC and does not turn into it. ^{36 10}	Review
THCVA (tetrahydrocannabivarinic acid) PubChem 59444416	Phytocannabinoid acid	Not read in the sources Not read	The acid form made by the plant. A review says natural decarboxylation, sped up by heat, turns THCVA into THCV. ^{37 10}	Review
Delta-8-THCV	Semi-synthetic isomer	Not reported in cannabis plants (per a review) Not applicable	The form used in the highest-amount human trial. A review reports lab antagonism of CB1 about two times weaker than delta-9-THCV (reported secondhand) and notes no human data to support a potency difference. PubChem CID was not confirmed by name search. ^{10 22}	Review and clinical study
CBDV (cannabidivarin) PubChem 11601669	Phytocannabinoid	Not read in the sources Detected in 100% of 80 over-the-counter CBD oils tested; amounts varied widely	A review says delta-8-THCV is made from CBDV by acid isomerization. Not the same molecule as THCV. ^{38 10 14}	Review and product analysis
11-nor-9-carboxy-THCV (THCV-COOH)	Metabolite	Not applicable	The main urine metabolite of THCV. It can read positive on a THC urine screen. PubChem CID not confirmed. ^{5 29}	Clinical study

Mechanisms, receptors and pathways

Target or pathway	Gene or receptor	What was found	Level
Cannabinoid receptor CB1	CB1 (CNR1)	Reviews say delta-9-THCV binds CB1 with high affinity (a 2025 perspective gives Ki 22 to 75.4 nM) and is a CB1 antagonist at most amounts studied, but acts as a weak agonist at higher amounts. A systematic review says it is a potent antagonist in vitro yet only occasionally produces effects in animals that come from CB1 blocking. In rat brain membranes THCV displaced a CB1 ligand (Ki about 290 nM) with no agonist action. In rats it partly substituted for THC at 3 mg/kg and blocked low-dose THC at 6 mg/kg. ^{21 19 10 12 15}	Review, lab and animal
Cannabinoid receptor CB2	CB2 (CNR2)	In cells carrying human CB2, THCV lowered cyclic AMP (EC50 38 nM), and in mice its anti-inflammatory and pain-reducing effects appeared to involve CB2 and CB1. Reviews call it a CB2 partial agonist in vitro, though some studies report agonism and others antagonism. ^{1 21 10}	Lab and animal
Antioxidant action	Not a single receptor	The authors of the Parkinson's model study link THCV's protection of dopamine-making nerve cells in rats to its antioxidant properties. ⁸	Animal research
Inflammation pathways in macrophages	PANX1/P2X7, NLRP3, IL-6/TYK-2/STAT-3, NF-kB	In human macrophage cells treated with LPS and ATP, THCV reduced markers of the NLRP3 inflammasome pathway, the IL-6/TYK-2/STAT-3 pathway and NF-kB activity. ⁹	Lab
Insulin signalling and energy use	Not stated in the abstract	In insulin-resistant liver and muscle cells THCV restored insulin signalling, and in mice it gave a brief rise in energy use and improved insulin sensitivity without clearly changing food intake or weight gain. ⁴⁰	Lab and animal
TRP channels	TRPV1 to TRPV4, TRPA1, TRPM8	A 2025 perspective says THC and THCV are similarly active at these channels, THC more potently, and that nearly all phytocannabinoids touch TRP channels, so the similarity is of little importance. ¹⁰	Review

Absorption, metabolism and elimination

Absorption: In the delta-8-THCV trial, swallowed delta-8-THCV in medium-chain triglyceride oil reached its peak in blood at a median of 3.8 to 5.0 hours, and exposure rose in step with dose; each doubling of dose raised total exposure 2.3- to 4.8-fold. A 2024 paper says swallowed delta-9-THCV was detected in only 3 of 37 plasma samples in a 10-man pilot, so no values could be reported (secondhand, from that paper's text). Human numbers for swallowed delta-9-THCV were not found in the abstracts read.
Distribution: In rats and mice, THCV, CBD, CBDV and CBG all entered the brain. For THCV in rats, injection gave higher brain levels than oral dosing. No human distribution data were read.
Metabolism: In the delta-8-THCV trial the main blood metabolite was 11-nor-9-carboxy-delta-8-THCV, with 11-hydroxy-delta-8-THCV also found. In human and mouse liver preparations, 29 metabolites of THCA and THCV were found; the abstract reports THCV changed into THC and CBD, which is unconfirmed and conflicts with a review.
Elimination: Half-life and elimination numbers were not in the sources read. In urine after delta-8-THCV, the main metabolite was 11-nor-9-carboxy-delta-8-THCV, heavily glucuronidated.
Bioavailability: Not reported for delta-9-THCV in the abstracts read.

^{28 29 4 25 5}

Isolated compounds versus whole extracts

"THCV" on a label can mean pure delta-9-THCV, pure delta-8-THCV, a hemp extract in which THCV is a small part, or a blend with CBD. The diabetes trial used THCV capsules alone and with CBD; the 10-man pilot used pure delta-9-THCV; the high-amount trial used delta-8-THCV in oil; the weight study used mouth strips that also held CBD. In mice, pure THCV cut food intake but a THCV-rich cannabis extract did not, possibly because of leftover THC; adding CBD overcame the THC effect. Results from one form cannot be assumed for another.

Nutritional composition

THCV is not a nutrient and has no nutritional claim. The FDA Q&A page read for this page does not mention THCV, and no FDA ruling on THCV as a supplement was found. Not legal advice.

10benefits and uses looked at

41studies and sources checked

Low certaintybest evidence rating found

16lab markers tracked in trials

1 low certainty2 very low certainty7 not enough evidence

What was looked at

The 10 benefits and uses checked for THCV (Tetrahydrocannabivarin), each with how strong the evidence is. Tap one to open it.

Type 2 diabetes: blood sugar (one small 13-week trial)Very low certainty
Weight and appetiteNot enough evidence
Brain responses to food cues and resting brain activity (healthy volunteers)Not enough evidence
Blunting some effects of THC (healthy volunteers)Very low certainty
Is THCV intoxicating? What small studies show at different amountsLow certainty
Parkinson's disease (animal models)Not enough evidence
Seizures and epilepsy-like activity (animal and lab)Not enough evidence
Pain and inflammation (animal and cell work)Not enough evidence
Alcohol drinking (rats)Not enough evidence
Psychotic-like symptoms and other mental health conditions (animal work)Not enough evidence

Lab markers tracked in the studies

Fasting blood glucoseBeta-cell function (HOMA2)HDL cholesterol (the trial's main target)Body weight and waist sizeBrain response to food cues (fMRI)Resting brain connectivity (default mode network)Heart rate rise after THCDelayed word recall and memory intrusions after THCRating: "feel a drug effect" and "like the drug effect"Urine THC drug screen resultSeizure incidence in ratsLoss of dopamine-making nerve cells (TH-positive neurons)Abnormal involuntary movements after L-DOPA (mice)Pain sensitivity and paw swelling (rodents)Voluntary alcohol intake (rats)Inflammation markers in human macrophage cells

What is THCV (Tetrahydrocannabivarin) good for?

The uses people ask about and how strong the evidence is for each. None is an approved use. Most rows are animal or lab research and say so; the human rows are small studies, and one missed its main target.

Type 2 diabetes: blood sugar (one 13-week trial)Very low certaintyOne pilot trial in 62 adults with type 2 diabetes compared THCV, CBD, mixtures and placebo. The main target, HDL cholesterol, did not change. THCV alone lowered fasting blood sugar, but that is a secondary finding from many measures, and it has not been repeated. Weight and appetite ("diet weed")Not enough evidenceThe only human weight result is from a 90-day study of mouth strips that combined THCV with CBD, whose abstract gives no numbers. In mice, pure THCV cut food intake in one study and did not in another. The nickname is ahead of the evidence. Brain responses to food cues (brain scans)Not enough evidenceTwo single-dose scan studies in 20 healthy volunteers each found changes in brain activity but no change in how people rated food or felt. They do not show any benefit. Blunting some effects of THCVery low certaintyIn 10 men, five days of THCV weakened some effects of a small intravenous THC dose, such as heart rate rise, but increased memory intrusions. The THC amount was too low to cause the problems under test. Whether THCV is intoxicating (depends on the amount and the form)Low certaintyAbout 10 mg of delta-9-THCV could not be told from placebo in small studies. At 100 and 200 mg of the man-made delta-8 form, volunteers reported a drug effect. In rats, THCV partly mimicked THC at one amount and blocked it at another. Parkinson's disease (animal models)Not enough evidenceIn rats and mice, THCV eased movement problems, protected dopamine-making nerve cells and lessened L-DOPA movement side effects. No study in people. Seizures (animal and lab)Not enough evidenceTHCV reduced epilepsy-like activity in rat brain slices and seizures in rats. No study in people with epilepsy. Pain and inflammation (animal and cell work)Not enough evidenceTHCV reduced swelling and pain behaviour in mice and rats and lowered inflammation markers in human cells in a dish. No human pain trial of THCV alone. Alcohol drinking (rats)Not enough evidenceIn rats that drank alcohol for months, three days of THCV reduced intake and preference, with mild sedation. No study in people. Psychotic-like symptoms and other mental health conditions (animal work)Not enough evidenceA 2025 systematic review found one clinical study among 23 and mostly animal results at moderate to high risk of bias. It says delta-9-THCV looked promising for psychotic-like symptoms in animals. No human evidence.

Benefits, one by one

Each card is a research question, not a promise. Tap a goal to filter. Open a card to see the studies, doses and limits.

Type 2 diabetes: blood sugar (one small 13-week trial)

Very low certainty

One small trial gave THCV, CBD, mixtures of the two, or placebo to 62 adults with type 2 diabetes for 13 weeks. The main target, HDL cholesterol, did not change. THCV alone lowered fasting blood sugar compared with placebo. The CBD and mixture groups showed no clear effect. It has not been repeated.

3 studiesCapsules with THCV 5 mg twice daily in the trial (study amount, not a…

Studies, doses and limits

What the trials found

One randomized, double-blind, placebo-controlled pilot trial in 62 adults with type 2 diabetes who did not use insulin (five groups, 13 weeks). A 2025 review calls the human trials preliminary and says larger ones are needed.

Results

Against placebo, THCV alone lowered fasting plasma glucose and improved some secondary measures (beta-cell function, adiponectin, apolipoprotein A). HDL cholesterol, the main target, was unaffected. None of the CBD or CBD plus THCV mixtures differed from placebo on the end points tested. THCV and CBD were well tolerated.

Effect sizes as reported

THCV alone versus placebo: fasting plasma glucose -1.2 mmol/L (P<0.05); HOMA2 beta-cell function -44.51 points (P<0.01); adiponectin -5.9 x 10^6 pg/mL (P<0.01); apolipoprotein A -6.02 umol/L (P<0.05). Signs are as printed in the abstract.

Why this rating

One pilot trial with about 12 people per group, a missed main target, many secondary measures tested, and no repeat by another group. One author is listed with a cannabis medicines company.

Form and dose studied

Capsules with THCV 5 mg twice daily in the trial (study amount, not advice). No amounts are advised here.

Who was studied

Adults with type 2 diabetes not treated with insulin.

Limits

Pilot size; the glucose result is a secondary finding; 13 weeks only; no data on people who use insulin or other glucose-lowering medicines in these abstracts.

Why researchers looked

In mice, THCV improved how the body handles sugar. Researchers wanted to know whether the same happens in people with type 2 diabetes.

Traditional use

No traditional use of isolated THCV is described in the sources read. THCV is a minor part of some cannabis plants.

Proposed mechanism Preliminary mechanism

THCV is thought to block the CB1 receptor at most amounts studied, which in mice is linked to better insulin sensitivity. This has not been shown to be the cause in people.

A proposed mechanism does not show that the effect happens in people.

A glucose-lowering effect means a doctor or pharmacist should know about any THCV product if you take diabetes medicines. Shop products may not match their labels. See the Safety tab.

^{13 20 40}

Weight and appetite

Not enough evidence

THCV is nicknamed "diet weed", but the evidence is thin and mixed. In mice, pure THCV cut food intake in one study and did not in another. In people, there is one small, company-linked 90-day study of mouth strips that combined THCV with CBD, and brain-scan studies that did not change how people rated food.

5 studiesMouth strips with THCV 8 mg or 16 mg plus CBD 10 mg or 20 mg daily (s…

Studies, doses and limits

What the trials found

A 90-day placebo-controlled study of 44 adults used mouth strips with THCV plus CBD, so effects cannot be put down to THCV alone. A 2025 perspective by authors from cannabis companies calls the human studies of blood sugar and appetite few. A single-dose brain-scan study in 20 people found no change in ratings of food.

Results

In the strip study, both strengths were linked to weight loss, smaller waist, lower systolic blood pressure and lower total and LDL cholesterol, with the higher strength better for weight; the abstract gives no numbers. In mice: pure THCV reduced food intake and weight at 3 mg/kg (Riedel 2009), but in obese mice THCV did not significantly change food intake or weight gain (Wargent 2013). A THCV-rich cannabis extract failed in the first study, possibly because of leftover THC.

Effect sizes as reported

No numbers are in the abstract of the strip study. Mouse studies used amounts that do not carry over to people.

Why this rating

The only weight result in people is from a combination product, a small study, and an abstract with no numbers, by an author whose company affiliation is shown in the record. Mouse results disagree.

Form and dose studied

Mouth strips with THCV 8 mg or 16 mg plus CBD 10 mg or 20 mg daily (study amounts, not advice). No amounts are advised here.

Who was studied

Adults, average age about 52, mostly women (31 of 44).

Limits

Combination product; small groups; how people were assigned and group sizes are not in the abstract; the author is affiliated with NeX Therapeutics and the paper cites unpublished studies of a hemp extract.

Why researchers looked

Drugs that fully block the CB1 receptor cut appetite but were withdrawn for mood side effects. THCV was proposed as a gentler blocker.

Traditional use

No traditional use of isolated THCV is described in the sources read.

Proposed mechanism Animal research

Thought to work through CB1 blocking in the brain's appetite and reward circuits. Mouse results do not agree: one study found less food intake, another found none.

A proposed mechanism does not show that the effect happens in people.

No safety numbers are in the abstract. See the Safety tab.

^{31 26 40 20 10}

Brain responses to food cues and resting brain activity (healthy volunteers)

Not enough evidence

Two small studies gave healthy volunteers a single 10 mg dose of THCV and scanned their brains. People did not feel different or rate food differently, but certain brain areas responded more to pleasant and unpleasant food cues and some brain networks connected differently. These are scans, not a treatment result.

2 studiesTHCV 10 mg by mouth, once (study amount, not advice).

Studies, doses and limits

What the trials found

Two randomized, double-blind, crossover studies in the same research group, 20 healthy volunteers each, single 10 mg oral dose versus placebo.

Results

Tudge 2015: no difference in ratings; THCV increased brain responses to chocolate (midbrain, anterior cingulate, caudate, putamen) and to unpleasant food cues (amygdala, insula, orbitofrontal cortex, caudate, putamen). Rzepa 2015: no difference in subjective experience; THCV reduced connectivity between the amygdala and the default mode network and increased connectivity in an executive control network.

Effect sizes as reported

Not given as numbers in the abstracts.

Why this rating

Single doses in healthy people measuring brain activity, not health outcomes. The authors' suggestion of a use in obesity is a possibility the studies did not test.

Form and dose studied

THCV 10 mg by mouth, once (study amount, not advice).

Who was studied

Healthy volunteers.

Limits

Single dose; 20 people each; no weight, eating or blood sugar outcome; scans cannot show benefit.

Why researchers looked

To see whether THCV, a CB1 blocker that leaves normal receptor activity intact, changes the brain's reward and aversion signals the way the withdrawn drug rimonabant did.

Proposed mechanism Preliminary mechanism

Consistent with CB1 blocking in reward and emotion circuits; the studies do not prove how.

A proposed mechanism does not show that the effect happens in people.

No adverse events are reported in the abstracts. See the Safety tab.

^{33 27}

Blunting some effects of THC (healthy volunteers)

Very low certainty

In a pilot of 10 men, five days of THCV before a small THC injection weakened some THC effects, such as the rise in heart rate and delayed word recall, and made THC feel less intense. It also increased memory intrusions. It is a very small study with a THC amount too low to cause the problems it was meant to block.

3 studiesTHCV 10 mg by mouth daily for 5 days, then THC 1 mg by vein (study am…

Studies, doses and limits

What the trials found

One placebo-controlled, double-blind crossover pilot in 10 men who had used cannabis fewer than 25 times (10 mg THCV by mouth daily for 5 days, then 1 mg THC by vein).

Results

THCV was well tolerated and not distinguishable from placebo. In this sample, THC did not significantly increase psychotic symptoms, paranoia or short-term memory problems, so there was little to block. THCV cut the THC heart-rate rise and the delayed recall impairment, nine of ten said THC felt weaker, and memory intrusions were significantly higher with THCV plus THC.

Effect sizes as reported

Heart rate Z=-2.193, p=0.028; delayed verbal recall Z=-2.201, p=0.028; memory intrusions Z=-2.155, p=0.031; nine of ten felt THC weaker (chi-square 6.4, p=0.011). Many outcomes were tested.

Why this rating

Ten men, many tests, intravenous THC rather than smoked or swallowed, and a THC amount too small to produce the problems under test. Findings go both ways (some THC effects blocked, one increased).

Form and dose studied

THCV 10 mg by mouth daily for 5 days, then THC 1 mg by vein (study amounts, not advice).

Who was studied

Healthy men with little cannabis use.

Limits

Small pilot; one route of THC; no psychotic effect from THC to block; short.

Why researchers looked

THCV blocks the CB1 receptor that THC activates, so it was proposed as a way to reduce unwanted THC effects such as paranoia and memory problems.

Proposed mechanism Preliminary mechanism

Competition at the CB1 receptor is the proposed route. Reviews say THCV's effects in living animals do not always follow its blocking in lab tests, and that it can act as a weak agonist at higher amounts.

A proposed mechanism does not show that the effect happens in people.

THCV did not make THC safe: it increased memory intrusions. Do not read this as a way to counter cannabis. See the Safety tab.

^{6 19 10}

Is THCV intoxicating? What small studies show at different amounts

Low certainty

THCV looks like THC but has a shorter side chain, and it is not an isomer of THC. At around 10 mg by mouth, small studies found people could not tell it from placebo. At 100 and 200 mg of a man-made delta-8 form, people reported feeling a drug effect, and euphoric mood was the most common mild side effect. In rats, THCV partly mimicked THC at one amount and blocked it at another.

8 studiesDelta-9-THCV 10 mg; delta-8-THCV 12.5 to 200 mg in single doses (stud…

Studies, doses and limits

What the trials found

At about 10 mg of delta-9-THCV by mouth: two small studies (Englund 2016, Jadoon 2016) report it indistinguishable from placebo, and two brain-scan studies of single 10 mg doses found no subjective change. At 12.5 to 200 mg of delta-8-THCV (a semi-synthetic form): a two-part placebo-controlled study in 21 adults found THC-like effects only at 100 and 200 mg. A 2025 review by authors from cannabis companies says these effects were of low magnitude compared with those of THC at under 10 mg.

Results

Delta-8-THCV trial: 55 of 60 adverse events were mild; euphoric mood was the most common; 100 and 200 mg raised ratings of "feel a drug effect" and "like the drug effect". In rats, the discrimination study found THCV partly substituted for THC at 3 mg/kg and reversed low-dose THC at 6 mg/kg; in mice THCV did not alter the THC cue and in other mouse tests it reduced movement and caused immobility only at higher doses.

Effect sizes as reported

Rat THC-like responding 54.6% +/- 17.82 at 3 mg/kg THCV. Human effect sizes are not in the abstracts.

Why this rating

Several small, consistent human studies at about 10 mg, but different forms (delta-9 and delta-8), different amounts, tiny samples, and some industry authorship. The delta-8 form is not the form found in cannabis plants.

Form and dose studied

Delta-9-THCV 10 mg; delta-8-THCV 12.5 to 200 mg in single doses (study amounts, not advice). No amounts are advised here.

Who was studied

Healthy adults; ten men in the delta-9 pilot; 21 adults in the delta-8 trial.

Limits

No study of delta-9-THCV at amounts above about 10 mg in people. The 100 and 200 mg results come from the man-made delta-8 isomer. Products sold as THCV may be either form.

Why researchers looked

THCV is often grouped with THC by regulators and sellers, so people ask whether it gets you high. The answer in the sources depends on the amount and the form.

Proposed mechanism Animal research

A review says THCV mostly blocks CB1 at the amounts in most studies but acts as a weak agonist at higher amounts. In rats, the effect was inverted-U shaped: partial THC-like at 3 mg/kg, blocking of a low THC amount at 6 mg/kg.

A proposed mechanism does not show that the effect happens in people.

Higher amounts produced THC-like effects, and almost all urine drug screens after active doses were positive for THC. See the Safety tab.

^{22 6 13 15 41 10 21 30}

Parkinson's disease (animal models)

Not enough evidence

In rodent models of Parkinson's disease, THCV eased movement problems, protected dopamine-making nerve cells, and delayed and lessened the movement side effects of L-DOPA. No study in people with Parkinson's disease was found.

3 studiesInjected THCV in rodents (not human amounts).

Studies, doses and limits

What the trials found

No human study found. A 2020 systematic review of minor cannabinoids lists THCV (0.025 to 2.5 mg/kg in animals) as promising in models of seizure, Huntington's and Parkinson's disease, and says all of it is animal and cell work.

Results

Acute THCV reduced the movement inhibition caused by 6-hydroxydopamine in rats. Chronic THCV reduced loss of dopamine-making nerve cells in rats and in LPS-treated mice. In mice given L-DOPA, THCV (2 mg/kg for two weeks) delayed the start of dyskinesia and reduced its intensity, and also lessened it once present.

Effect sizes as reported

No numbers are given in the abstracts.

Why this rating

Rodent models only; no human data. The authors of the dyskinesia study say clinical meaning needs study.

Form and dose studied

Injected THCV in rodents (not human amounts).

Who was studied

Rats and mice.

Limits

Models do not match human Parkinson's disease; no dose-finding in people.

Why researchers looked

THCV can block CB1 receptors, activate CB2 receptors and act as an antioxidant, three properties researchers linked to Parkinson's disease models.

Traditional use

No traditional use of isolated THCV is described in the sources read.

Proposed mechanism Animal research

In rats and mice the effects were linked to antioxidant action and, in one model, to CB2 receptors. Nothing is known about how this would work in people.

A proposed mechanism does not show that the effect happens in people.

No human safety information for this use. See the Safety tab.

^{8 7 32}

Seizures and epilepsy-like activity (animal and lab)

Not enough evidence

In rat brain slices and in rats with chemically induced seizures, THCV reduced epilepsy-like activity. No trial in people with epilepsy was found.

2 studiesBrain slices and rats (not human amounts).

Studies, doses and limits

What the trials found

No human study found. A 2020 systematic review lists THCV as promising in seizure models.

Results

At 20 micromolar or more, THCV reduced epilepsy-like bursts in rat brain slices. At 0.25 mg/kg in rats it significantly reduced the incidence of seizures caused by pentylenetetrazole (PTZ).

Effect sizes as reported

No numbers beyond the dose are in the abstract.

Why this rating

One 2010 lab and rat study with a single seizure model, and no human data.

Form and dose studied

Brain slices and rats (not human amounts).

Who was studied

Rat tissue and rats.

Limits

One seizure model; no comparison with an approved seizure medicine in the abstract.

Why researchers looked

Other cannabis compounds have been studied in epilepsy, and THCV's action on CB1 receptors was proposed to calm overactive nerve activity.

Traditional use

No traditional use of isolated THCV is described in the sources read.

Proposed mechanism Laboratory research

Consistent with CB1 receptor binding (Ki about 290 nM) without agonist action in the same study. Not shown in people.

A proposed mechanism does not show that the effect happens in people.

Ask a doctor before changing any seizure medicine. See the Safety tab.

^{12 32}

Pain and inflammation (animal and cell work)

Not enough evidence

In mice and rats with paw or knee inflammation, THCV reduced swelling and pain sensitivity, and in cells it lowered inflammation markers. No human pain trial of THCV alone was found.

3 studiesInjections in rodents and treatments of cells (not human amounts).

Studies, doses and limits

What the trials found

No human trial found.

Results

Mice: THCV (0.3 or 1 mg/kg) reduced paw swelling and pain behaviour in the formalin test at 1 and 5 mg/kg (Bolognini 2010). Rats with knee inflammation: THCV reduced mechanical hyperalgesia and recovered body weight (Poceviciute 2026). Cells: reduced inflammation markers (Gojani 2023).

Effect sizes as reported

No numbers in the abstracts for the 2026 rat study.

Why this rating

Animal and cell work only. Results across rodent models are consistent in direction but there is no human evidence.

Form and dose studied

Injections in rodents and treatments of cells (not human amounts).

Who was studied

Mice, rats and human cell lines.

Limits

No human data; short studies.

Why researchers looked

THCV activates the CB2 receptor, which is linked to inflammation control, while blocking CB1.

Traditional use

No traditional use of isolated THCV is described in the sources read.

Proposed mechanism Laboratory research

THCV activated CB2 in cells (EC50 38 nM); in mice the effects seemed to involve CB1 and CB2. In human macrophage cells it lowered NLRP3 inflammasome, IL-6/STAT-3 and NF-kB markers.

A proposed mechanism does not show that the effect happens in people.

No human safety information for this use. See the Safety tab.

^{1 23 9}

Alcohol drinking (rats)

Not enough evidence

In rats that drank alcohol voluntarily for months, three days of THCV reduced how much they drank and how much they preferred it, with a mild sedative effect. No study in people with alcohol use disorder was found.

1 studiesInjections in rats (amounts not in the abstract).

Studies, doses and limits

What the trials found

No human study found.

Results

THCV and CBN reduced alcohol intake and preference and had a mild sedative effect; CBD had a minor effect on intake. None caused discomfort or distress in the rats.

Effect sizes as reported

No numbers in the abstract.

Why this rating

A rat model with three days of dosing; no human data.

Form and dose studied

Injections in rats (amounts not in the abstract).

Who was studied

Male Wistar rats.

Limits

One lab; male rats only; short.

Why researchers looked

CB1 blockers reduce alcohol drinking in animals but the withdrawn drug rimonabant caused mood side effects, so THCV was tested as a gentler option.

Traditional use

No traditional use of isolated THCV is described in the sources read.

Proposed mechanism Animal research

THCV is a CB1 antagonist in lab tests. The rat study does not show how it reduced drinking.

A proposed mechanism does not show that the effect happens in people.

Sedation was seen in rats. Mixing with alcohol has not been studied in people. See the Safety tab.

²⁴

Psychotic-like symptoms and other mental health conditions (animal work)

Not enough evidence

A 2025 systematic review of minor cannabinoids found only one clinical study among 23, with mostly animal results and moderate to high risk of bias. It reports that delta-9-THCV showed promise for psychotic-like symptoms in animals. No evidence in people was found.

2 studiesNot applicable.

Studies, doses and limits

What the trials found

No human trial of THCV for any mental health condition was found. The review's single clinical study is not described in its abstract.

Results

The review says results were heterogeneous and risk of bias moderate to high in several articles, and names delta-9-THCV as of interest for psychotic-like symptoms.

Effect sizes as reported

Not given.

Why this rating

Animal work only, with high risk of bias. The review's abstract names THCV for psychotic-like symptoms but no human result.

Who was studied

Animals, with one unspecified clinical study.

Limits

The abstract does not say which cannabinoid the clinical study tested.

Why researchers looked

THCV blocks CB1, which is involved in anxiety, mood and addiction circuits, and was proposed as a gentler alternative to older CB1 blockers.

Traditional use

No traditional use of isolated THCV is described in the sources read.

Proposed mechanism Preclinical

Not established. A review says THCV does not behave like rimonabant, a withdrawn CB1 blocker that raised depression and anxiety, but this is based on lab and animal work.

A proposed mechanism does not show that the effect happens in people.

THC raises the risk of psychosis in some people; THCV has no data in people with psychosis. See the Safety tab and ask a doctor.

^{2 19}

Connections to the rest of health

How THCV (Tetrahydrocannabivarin) connects to the rest of our health knowledge graph. Every link says what kind of connection it is. A safety link (for example to the liver) is a warning, not a benefit. A study that merely mentions a topic never creates a benefit link.

Explore every connection: goals, body systems, organs, symptoms, genes

Kind of connection Connected to Search

A. Wellness goals

Connected to	Evidence status	Context	Studies
Blood Sugar Balance	Very low certainty	Type 2 diabetes: blood sugar (one small 13-week trial): One small trial gave THCV, CBD, mixtures of the two, or placebo to 62 adults with type 2 diabetes for 13 weeks. The main target, HDL cholesterol, did not change. THCV alone lowered fasting blood sugar compared with placebo. The CBD and mixture groups showed no clear effect. It has not been repeated.	^{13 20 40}
Metabolic Health	Very low certainty	Type 2 diabetes: blood sugar (one small 13-week trial): One small trial gave THCV, CBD, mixtures of the two, or placebo to 62 adults with type 2 diabetes for 13 weeks. The main target, HDL cholesterol, did not change. THCV alone lowered fasting blood sugar compared with placebo. The CBD and mixture groups showed no clear effect. It has not been repeated.	^{13 20 40}
Weight Management	Not enough evidence	Weight and appetite: THCV is nicknamed "diet weed", but the evidence is thin and mixed. In mice, pure THCV cut food intake in one study and did not in another. In people, there is one small, company-linked 90-day study of mouth strips that combined THCV with CBD, and brain-scan studies that did not change how people rated food.	^{31 26 40 20 10}
Healthy Appetite	Not enough evidence	Weight and appetite: THCV is nicknamed "diet weed", but the evidence is thin and mixed. In mice, pure THCV cut food intake in one study and did not in another. In people, there is one small, company-linked 90-day study of mouth strips that combined THCV with CBD, and brain-scan studies that did not change how people rated food.	^{31 26 40 20 10}
Weight Management	Not enough evidence	Brain responses to food cues and resting brain activity (healthy volunteers): Two small studies gave healthy volunteers a single 10 mg dose of THCV and scanned their brains. People did not feel different or rate food differently, but certain brain areas responded more to pleasant and unpleasant food cues and some brain networks connected differently. These are scans, not a treatment result.	^{33 27}
Brain Health	Not enough evidence	Brain responses to food cues and resting brain activity (healthy volunteers): Two small studies gave healthy volunteers a single 10 mg dose of THCV and scanned their brains. People did not feel different or rate food differently, but certain brain areas responded more to pleasant and unpleasant food cues and some brain networks connected differently. These are scans, not a treatment result.	^{33 27}
Mental Wellbeing	Very low certainty	Blunting some effects of THC (healthy volunteers): In a pilot of 10 men, five days of THCV before a small THC injection weakened some THC effects, such as the rise in heart rate and delayed word recall, and made THC feel less intense. It also increased memory intrusions. It is a very small study with a THC amount too low to cause the problems it was meant to block. Is THCV intoxicating? What small studies show at different amounts: THCV looks like THC but has a shorter side chain, and it is not an isomer of THC. At around 10 mg by mouth, small studies found people could not tell it from placebo. At 100 and 200 mg of a man-made delta-8 form, people reported feeling a drug effect, and euphoric mood was the most common mild side effect. In rats, THCV partly mimicked THC at one amount and blocked it at another.	^{6 19 10 22 13 15 41 21 30}
Brain Health	Not enough evidence	Parkinson's disease (animal models): In rodent models of Parkinson's disease, THCV eased movement problems, protected dopamine-making nerve cells, and delayed and lessened the movement side effects of L-DOPA. No study in people with Parkinson's disease was found. Seizures and epilepsy-like activity (animal and lab): In rat brain slices and in rats with chemically induced seizures, THCV reduced epilepsy-like activity. No trial in people with epilepsy was found.	^{8 7 32 12}
Mobility Support	Not enough evidence	Parkinson's disease (animal models): In rodent models of Parkinson's disease, THCV eased movement problems, protected dopamine-making nerve cells, and delayed and lessened the movement side effects of L-DOPA. No study in people with Parkinson's disease was found.	^{8 7 32}
Pain Relief	Not enough evidence	Pain and inflammation (animal and cell work): In mice and rats with paw or knee inflammation, THCV reduced swelling and pain sensitivity, and in cells it lowered inflammation markers. No human pain trial of THCV alone was found.	^{1 23 9}
Inflammation Balance	Not enough evidence	Pain and inflammation (animal and cell work): In mice and rats with paw or knee inflammation, THCV reduced swelling and pain sensitivity, and in cells it lowered inflammation markers. No human pain trial of THCV alone was found.	^{1 23 9}
Mental Wellbeing	Not enough evidence	Alcohol drinking (rats): In rats that drank alcohol voluntarily for months, three days of THCV reduced how much they drank and how much they preferred it, with a mild sedative effect. No study in people with alcohol use disorder was found. Psychotic-like symptoms and other mental health conditions (animal work): A 2025 systematic review of minor cannabinoids found only one clinical study among 23, with mostly animal results and moderate to high risk of bias. It reports that delta-9-THCV showed promise for psychotic-like symptoms in animals. No evidence in people was found.	^{24 2 19}
Anxiety Support	Not enough evidence	Psychotic-like symptoms and other mental health conditions (animal work): A 2025 systematic review of minor cannabinoids found only one clinical study among 23, with mostly animal results and moderate to high risk of bias. It reports that delta-9-THCV showed promise for psychotic-like symptoms in animals. No evidence in people was found.	^{2 19}

B. Body systems

Connected to	Kind of connection	Evidence status	Context	Studies
Endocrine System	Biological association	Very low certainty	Studied for: Type 2 diabetes: blood sugar (one small 13-week trial)	^{13 20 40}
Metabolism Weight	Biological association	Very low certainty	Studied for: Type 2 diabetes: blood sugar (one small 13-week trial) Studied for: Weight and appetite	^{13 20 40 31 26 10}
Nervous System	Biological association	Not enough evidence	Studied for: Brain responses to food cues and resting brain activity (healthy volunteers) Studied for: Blunting some effects of THC (healthy volunteers)	^{33 27 6 19 10 22 13 15 41 21 30 8 7 32 12 24 2}
Cardiovascular System	Biological association	Very low certainty	Studied for: Blunting some effects of THC (healthy volunteers)	^{6 19 10}
Pain Inflammation	Biological association	Not enough evidence	Studied for: Pain and inflammation (animal and cell work)	^{1 23 9}
Immune System	Biological association	Not enough evidence	Studied for: Pain and inflammation (animal and cell work)	^{1 23 9}
Stress Mood	Biological association	Not enough evidence	Studied for: Psychotic-like symptoms and other mental health conditions (animal work)	^{2 19}

C. Body parts and organs

Connected to	Kind of connection	Evidence status	Context	Studies
Endocrine system (blood sugar)		Very low certainty	Lowered fasting glucose against placebo in 62 adults; the trial's main target (HDL) was missed. Preparation or compound: THCV 5 mg twice daily for 13 weeks	¹³
Nervous system		Very low certainty	No effect felt at about 10 mg; THC-like effects at 100 and 200 mg of delta-8-THCV; brain-scan changes with no change in ratings. Preparation or compound: THCV 10 mg (delta-9) or 12.5 to 200 mg (delta-8) in volunteers	^{6 22 33 27}

I. Biomarkers

Connected to	Kind of connection	Evidence status	Context	Studies
Fasting blood glucose	Biological association	Very low certainty	Measured in trials: lowered. A lab change is not the same as a health benefit.	^{13 40}
Beta-cell function (HOMA2)	Biological association	Very low certainty	Measured in trials: improved. A lab change is not the same as a health benefit.	¹³
HDL cholesterol (the trial's main target)	Biological association	Very low certainty	Measured in trials: no-change. A lab change is not the same as a health benefit.	¹³
Body weight and waist size	Biological association	Not enough evidence	Measured in trials: lowered. A lab change is not the same as a health benefit.	^{31 40 26}
Brain response to food cues (fMRI)	Biological association	Not enough evidence	Measured in trials: raised. A lab change is not the same as a health benefit.	³³
Resting brain connectivity (default mode network)	Biological association	Not enough evidence	Measured in trials: mixed. A lab change is not the same as a health benefit.	²⁷
Heart rate rise after THC	Biological association	Very low certainty	Measured in trials: lowered. A lab change is not the same as a health benefit.	⁶
Delayed word recall and memory intrusions after THC	Biological association	Very low certainty	Measured in trials: mixed. A lab change is not the same as a health benefit.	⁶
Rating: "feel a drug effect" and "like the drug effect"	Biological association	Low certainty	Measured in trials: raised. A lab change is not the same as a health benefit.	^{22 6}
Urine THC drug screen result	Biological association	Low certainty	Measured in trials: raised. A lab change is not the same as a health benefit.	^{22 29}
Seizure incidence in rats	Biological association	Not enough evidence	Measured in trials: lowered (in rats). A lab change is not the same as a health benefit.	¹²
Loss of dopamine-making nerve cells (TH-positive neurons)	Biological association	Not enough evidence	Measured in trials: lowered (in animals). A lab change is not the same as a health benefit.	⁸
Abnormal involuntary movements after L-DOPA (mice)	Biological association	Not enough evidence	Measured in trials: lowered (in mice). A lab change is not the same as a health benefit.	⁷
Pain sensitivity and paw swelling (rodents)	Biological association	Not enough evidence	Measured in trials: lowered (in animals). A lab change is not the same as a health benefit.	^{1 23}
Voluntary alcohol intake (rats)	Biological association	Not enough evidence	Measured in trials: lowered (in rats). A lab change is not the same as a health benefit.	²⁴
Inflammation markers in human macrophage cells	Biological association	Not enough evidence	Measured in trials: lowered (in cells). A lab change is not the same as a health benefit.	⁹

J. Genes, receptors and enzymes

Connected to	Kind of connection	Evidence status	Context	Studies
CB1 receptor (CNR1)		Low certainty	Binds CB1 with high affinity; acts as an antagonist at most amounts and a weak agonist at higher amounts, per reviews. Preparation or compound: Delta-9-THCV in cells and animals	^{21 19 10}
CB2 receptor (CNR2)		Low certainty	Partial agonist at CB2 in cells (EC50 38 nM); linked to anti-inflammatory effects in mice. Preparation or compound: Delta-9-THCV in cells and mice	^{1 21}
CNR1 (CB1 receptor)	Preliminary mechanism	Review and animal	The main target; THCV mostly blocks it at lower amounts and may act as a weak agonist at higher ones.	^{21 19 15}
CNR2 (CB2 receptor)	Preliminary mechanism	Lab and animal	THCV is a CB2 partial agonist in cells, linked to anti-inflammatory effects in mice.	¹
PANX1 and P2RX7	Preliminary mechanism	Lab	THCV lowered markers of this inflammation pathway in human macrophage cells.	⁹

L. Active compounds

Connected to	Kind of connection	Evidence status	Context	Studies
THC		Very low certainty	Weakened some THC effects and increased memory intrusions in 10 men. Preparation or compound: THCV 10 mg with intravenous THC	⁶
THC (delta-9-tetrahydrocannabinol)	Biological association	Review	The best-known compound of the same shape. THC is a potent CB1 partial agonist and causes the high; THCV has a three-carbon side chain and, in most studies, blocks CB1. THCV is not made from THC and does not turn into it. Preparation or compound: Not read in the sources	^{36 10}
THCVA (tetrahydrocannabivarinic acid)	Biological association	Review	The acid form made by the plant. A review says natural decarboxylation, sped up by heat, turns THCVA into THCV. Preparation or compound: Not read in the sources	^{37 10}
Delta-8-THCV	Biological association	Review and clinical study	The form used in the highest-amount human trial. A review reports lab antagonism of CB1 about two times weaker than delta-9-THCV (reported secondhand) and notes no human data to support a potency difference. PubChem CID was not confirmed by name search. Preparation or compound: Not reported in cannabis plants (per a review)	^{10 22}
CBDV (cannabidivarin)	Biological association	Review and product analysis	A review says delta-8-THCV is made from CBDV by acid isomerization. Not the same molecule as THCV. Preparation or compound: Not read in the sources	^{38 10 14}
11-nor-9-carboxy-THCV (THCV-COOH)	Biological association	Clinical study	The main urine metabolite of THCV. It can read positive on a THC urine screen. PubChem CID not confirmed.	^{5 29}

Each connection is stored with the ingredient, the connected record, the kind of connection, the evidence status, the supporting studies, the preparation or compound involved, and a review date (last reviewed October 25, 2026).

Evidence at a glance: what changed in 9 lab markers

Tap a number to show only those markers. Counts are markers, not people.

Metabolic1 Other332

The evidence

The research centre for THCV (Tetrahydrocannabivarin). Every record here was checked against PubMed or the publisher's page; we never list a study we have not verified.

Evidence by outcome

Type 2 diabetes: blood sugar (one small 13-week trial) 3 studies · 62 people in trials Very low certainty Weight and appetite 5 studies Not enough evidence Brain responses to food cues and resting brain activity (healthy volunteers) 2 studies Not enough evidence Blunting some effects of THC (healthy volunteers) 3 studies Very low certainty Is THCV intoxicating? What small studies show at different amounts 8 studies · 62 people in trials Low certainty Parkinson's disease (animal models) 3 studies Not enough evidence Seizures and epilepsy-like activity (animal and lab) 2 studies Not enough evidence Pain and inflammation (animal and cell work) 3 studies Not enough evidence Alcohol drinking (rats) 1 study Not enough evidence Psychotic-like symptoms and other mental health conditions (animal work) 2 studies Not enough evidence

Bars show how many studies we found for each outcome, not how well it works. People are added up across trials only (reviews are not added, to avoid double counting).

How we rate evidence

High certainty

Several well-run trials or reviews agree; further research is unlikely to change the picture much.

Moderate certainty

Good trials point the same way, but some doubt remains.

Low certainty

Small, short or inconsistent trials. The finding could change with better research.

Very low certainty

Very little or very weak human data. Treat as a possibility only.

Mixed findings

Trials or reviews disagree with each other.

Not enough evidence

Not enough human research to say either way.

Evidence against

Good research found no benefit, or found harm.

We take the reviewers' own risk-of-bias and GRADE statements where they exist, and otherwise judge from study size, design, consistency, directness and whether a product matches what is sold. Many publications do not make evidence high. Method note: We searched PubMed and read the abstracts of the studies cited, read the FDA cannabis questions-and-answers page, a Congressional Research Service summary of the new US hemp definition and the UK Misuse of Drugs Act schedule, and read the full text of two open-access papers. Compound identity was checked in PubChem. Lab numbers come from a table of published data and are not our own testing.

Study library: every study we checked 41

Design Research type Year from Search

Study	Design	People	Product, dose, length	Result
Bolognini 2010 The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol · PMID 20590571 · DOI	Animal and lab animal	Hamster-ovary cells carrying human CB2; mouse spleen membranes; mice with paw inflammation	Delta-9-THCV 0.3 to 5 mg/kg by injection in mice (not human amounts) Acute · vs Vehicle and receptor blockers	THCV activated CB2 in cells (EC50 38 nM). At 0.3 or 1 mg/kg it reduced paw swelling in mice, and it reduced pain behaviour in the formalin test at 1 and 5 mg/kg. The effects appeared to involve CB2 and CB1 receptors. Methods, limits and funding Outcomes: CB2 activation; paw swelling and pain behaviour Limitations: Mouse and cell work only. Funding and conflicts: US NIDA grants listed; no conflict listed. Read: abstract
Cammà 2025 Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review. Eur Neuropsychopharmacol · PMID 39541799 · DOI	Systematic review review	22 preclinical and 1 clinical study of minor cannabinoids in psychiatric conditions	Minor cannabinoids including delta-9-THCV and delta-8-THCV	The review found mostly animal work with heterogeneous results and moderate to high risk of bias in several articles. It says delta-8-THCV showed potential for nicotine addiction and delta-9-THCV for psychotic-like symptoms (preclinical). Methods, limits and funding Outcomes: Anxiety, depression, psychosis, addiction, eating disorders and other conditions Limitations: The abstract does not say which cannabinoid the single clinical study tested or give THCV results; the abstract spells the compound as "tetrahydrocannabidivarin" in one place, which looks like a slip for THCV. Funding and conflicts: No conflicts declared. Read: abstract
Congressional Research Service 2026 Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (CRS In Focus IF13136), updated September 28, 2026 CRS In Focus · Source	Authoritative guidance n/a	n/a	n/a	Says P.L. 119-37 changes the hemp definition to total THC including THCA at no more than 0.3% dry weight; excludes hemp-derived cannabinoid products containing cannabinoids that are not capable of being naturally produced by the plant, or that were synthesized or manufactured outside the plant; limits final products to 0.4 mg per container of total THC and other cannabinoids with similar effects. Most parts were delayed to December 11, 2026. As of September 28, 2026 the FDA lists of cannabinoids had not been published. The summary does not name THCV. Methods, limits and funding Outcomes: How the US federal definition of hemp is changing Limitations: A three-page summary; it does not say how THCV products are treated. Read: full-text
Deiana 2012 Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) · PMID 21796370 · DOI	Animal research animal	Mice and rats	CBD, CBDV, delta-9-THCV and CBG by mouth or injection THCV 30 mg/kg in rats (rat amount) Single dose · vs Different vehicles	All the phytocannabinoids entered the brain. In rats, oral dosing gave higher brain levels for CBD and CBDV but not for THCV and CBG, for which injection was more effective. Methods, limits and funding Outcomes: Blood and brain levels Limitations: Animal pharmacokinetics only. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
ElSohly 2001 Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol · PMID 11599601 · DOI	Crossover trial	4 4 volunteers (male and female)	Marinol (synthetic THC) by mouth; THC in a placebo-marijuana cigarette; marijuana cigarette with THC and THCV Marinol 15 mg; smoked THC 16.88 mg; smoked marijuana 2.11% THC and 0.12% THCV (study amounts, not advice) Three sessions a week apart · vs Each person received all three	The authors report that the THCV metabolite (THCV-COOH) was found in urine only after marijuana and not after Marinol, so it could separate marijuana use from Marinol use. The abstract states this finding but gives no numbers. THCV-COOH detected after marijuana, not after Marinol, in four people. Methods, limits and funding Outcomes: Urine THC-COOH and THCV-COOH over a week Limitations: Four people; the lab method is old; results in the abstract are stated, not numbered. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Englund 2016 The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol · PMID 26577065 · DOI	Rct crossover	10 10 men who used cannabis (fewer than 25 times), healthy	Pure THCV by mouth, then THC by vein on day 5 THCV 10 mg daily for 5 days, then THC 1 mg by vein on day 5 (study amounts, not advice) 5 days per arm, crossover · vs Placebo	THCV was well tolerated and could not be told from placebo. In this small group THC did not significantly raise psychotic symptoms, paranoia or short-term memory problems, so there was little for THCV to block there. Delayed verbal recall was impaired by THC only under placebo (Z=-2.201, p=0.028). THCV reduced the THC rise in heart rate (Z=-2.193, p=0.028). Nine of ten said THC felt weaker or less intense after THCV (chi-square 6.4, p=0.011). THCV with THC significantly increased memory intrusions (Z=-2.155, p=0.031). THCV blocked some THC effects (recall, heart rate, intensity) and increased another (memory intrusions). Methods, limits and funding Outcomes: Safety and tolerability; THC-induced psychotic-like symptoms, memory, heart rate and subjective intensity Limitations: Ten men, a pilot; THC was given by vein (not smoked or swallowed); the THC amount was too low to cause the psychotic-like and memory effects the study aimed to block, which the authors say limits conclusions. Many outcomes tested. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Espadas 2020 Beneficial effects of the phytocannabinoid Δ(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease. Neurobiol Dis · PMID 32387338 · DOI	Animal research animal	Mutant mice (Pitx3ak) given repeated L-DOPA to cause dyskinesia, a model of Parkinson's treatment side effects	Delta-9-THCV by injection 2 mg/kg for two weeks (mouse amount) Two weeks; or 3 days once signs were present · vs Vehicle with L-DOPA	When given with L-DOPA from the start, THCV delayed the appearance of dyskinesia signs and lessened them, with lower FosB and pAcH3. It also reduced the intensity once signs were already present. Methods, limits and funding Outcomes: Abnormal involuntary movements, activity, and brain markers (FosB, histone pAcH3) Limitations: One mouse model; the authors say clinical meaning in people needs more study. Funding and conflicts: Authors declare no conflict of interest. Read: abstract
García 2011 Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease. Br J Pharmacol · PMID 21323909 · DOI	Animal research animal	Rats lesioned with 6-hydroxydopamine and mice lesioned with LPS (models of Parkinson's disease)	Delta-9-THCV by injection Not given in the abstract Acute and chronic · vs Vehicle; also a CB2 agonist and a CBD-rich extract	Acute THCV reduced the movement problems in the 6-hydroxydopamine model. Chronic THCV reduced loss of tyrosine-hydroxylase-positive nerve cells in the substantia nigra; the effect seemed to relate to antioxidant properties and, in the LPS model, to CB2 receptors. Methods, limits and funding Outcomes: Movement and loss of dopamine-making nerve cells Limitations: Rodent models; not human Parkinson's disease. Funding and conflicts: US NIDA grant listed; no conflict listed. Read: abstract
Gojani 2023 Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. Molecules · PMID 37764262 · DOI	Lab in-vitro	Human THP-1 macrophage cells in a dish	THCV, CBC and CBN Various concentrations Hours · vs Vehicle and LPS/ATP	THCV reduced markers of the NLRP3 inflammasome pathway (PANX1/P2X7), the IL-6/TYK-2/STAT-3 pathway and NF-kB activity in cells. Methods, limits and funding Outcomes: Inflammation pathway markers Limitations: Cells in a dish; no animals or people. Funding and conflicts: Mitacs funding; authors declare no conflict. Read: abstract
Haghdoost 2025 Tetrahydrocannabivarin is Not Tetrahydrocannabinol. Cannabis Cannabinoid Res · PMID 38995871 · DOI	Narrative review review	Reviews and studies of THCV in cells, animals and people	THCV (delta-9 and delta-8)	States that THCV is not an isomer of THC and that no known pathway turns THC into THCV; says delta-9-THCV acts mostly as a CB1 antagonist at most amounts in the literature, but may act as a weak agonist at higher amounts; says 10 mg oral THCV was indistinguishable from placebo in two studies while 100 and 200 mg of delta-8-THCV gave low-magnitude THC-like effects; says most THCV consumer products hold under 5 mg; argues THCV and THC should not be grouped together by regulators. Methods, limits and funding Outcomes: How THCV differs from THC (chemistry, receptors, human studies) Limitations: A short perspective, not a systematic review. The authors have industry ties and argue for a regulatory position. Funding and conflicts: No funding. Authors are employees or consultants of cannabis companies (Nalu Bio, Charlotte's Web) and former employees of Canopy Growth Corporation, which funded the delta-8-THCV trial the review cites. Read: full-text
Hambidge 2025 Validated LC-MS/MS methodology for the quantification of CBD, trace level THCA and UK controlled cannabinoids (Δ(9)-THC, Δ(8)-THC, CBN and THCV) in food samples. Anal Methods · PMID 39832132 · DOI	Cross sectional product analysis product-analysis	148 148 CBD edible products in the UK	CBD foods	In 13 products (9%) CBD was below the limit of quantification. Of the other 135, 66% had detectable amounts of one or more controlled cannabinoids. The paper names THCV among the UK controlled cannabinoids it measured; the abstract does not give a THCV-only result. Methods, limits and funding Outcomes: CBD content and UK-controlled cannabinoids (delta-9-THC, delta-8-THC, CBN and THCV) Limitations: Aggregate result for four cannabinoids; no THCV-only figure in the abstract. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Hill 2010 Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia · PMID 20196794 · DOI	Animal and lab animal	Rat brain slices; rat brain membranes; rats given PTZ to induce seizures	Delta-9-THCV 10 to 50 micromolar on slices; 0.025 to 2.5 mg/kg in rats (not human amounts) Acute · vs Vehicle	At 20 micromolar or more, THCV reduced epilepsy-like bursts in slices. THCV displaced a CB1 ligand (Ki about 290 nM) without agonist action. At 0.25 mg/kg in rats it significantly reduced the incidence of seizures caused by PTZ. Methods, limits and funding Outcomes: Epilepsy-like activity in brain slices; CB1 binding; seizure incidence in rats Limitations: Lab and rat work only; one seizure model. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Jadoon 2016 Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care · PMID 27573936 · DOI	Controlled trial	62 62 adults with type 2 diabetes not treated with insulin	THCV, or CBD, or both, as study capsules (form not stated in the abstract) THCV 5 mg twice daily; CBD 100 mg twice daily; or mixtures of the two (study amounts, not advice) 13 weeks · vs Matched placebo	The main target was missed: HDL cholesterol was unaffected. Against placebo, THCV alone lowered fasting blood glucose and improved some secondary measures (beta-cell function, adiponectin, apolipoprotein A). Neither CBD nor the CBD plus THCV mixtures differed from placebo on the end points tested. CBD and THCV were well tolerated. THCV alone vs placebo: fasting plasma glucose difference -1.2 mmol/L (P<0.05); HOMA2 beta-cell function -44.51 points (P<0.01); adiponectin -5.9 x 10^6 pg/mL (P<0.01); apolipoprotein A -6.02 umol/L (P<0.05). Signs are as printed in the abstract. Methods, limits and funding Outcomes: Main target: change in HDL cholesterol. Many secondary measures: blood sugar, blood fats, insulin sensitivity, body weight, liver fat, appetite, inflammation markers, hormones, safety. Limitations: A pilot study with five groups and 62 people in all (about 12 per group if split evenly; the abstract does not give group sizes). The main target was missed, and the glucose and other results are secondary findings from many measures, with no correction for that stated in the abstract. Only 13 weeks. Funding and conflicts: Funders listed in PubMed: Diabetes UK and the Medical Research Council. One author is listed with GW Pharmaceuticals, a cannabis medicines company. Read: abstract
Johnson 2025 Minor Cannabinoid Profile of Unregulated Cannabidiol Products. Cannabis Cannabinoid Res · PMID 39478329 · DOI	Cross sectional product analysis product-analysis	80 80 hemp-derived CBD oil products bought online and in Kentucky shops; Epidiolex as a control	Over-the-counter CBD oils · vs Epidiolex (regulated medicine)	Minor cannabinoids were common and varied widely from trace amounts to several mg/mL. The most frequently detected were CBDV (100%), CBG (77%), CBC (72%), CBN (67%), CBL (67%) and CBDA (51%); delta-8-THC was not detected. The authors say these amounts are largely absent from labels. The abstract does not give a THCV-specific result. Methods, limits and funding Outcomes: Amounts of 15 minor cannabinoids, including delta-9-THCV and its acid Limitations: Not products sold as THCV; the abstract does not report how often THCV was found. Funding and conflicts: NIDA grants listed; no conflict listed. Read: abstract
Kayir 2025 Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats. Biomolecules · PMID 41008636 · DOI	Animal research animal	16 Male rats trained to tell THC from vehicle	Delta-9-THCV and THC by injection THCV 0.75 to 6 mg/kg; THC 0.325 to 3 mg/kg (rat amounts) Acute tests · vs Vehicle	THCV gave an inverted-U-shaped pattern: at 3 mg/kg it partly substituted for THC (54.6% +/- 17.82), and at 6 mg/kg it reversed the effect of a low THC amount (0.75 mg/kg). Blood levels of THC and its metabolite did not change when THCV was added. The authors say THCV can partly mimic or block THC in a dose-dependent way, possibly as a partial CB1 agonist. Partial substitution at 3 mg/kg; blocking at 6 mg/kg against low-dose THC. Methods, limits and funding Outcomes: Whether THCV feels like THC to rats, or blocks THC Limitations: Sixteen male rats; one test; says nothing about human feelings. Funding and conflicts: Canadian research council funding; funders had no role. Read: abstract
Kulpa 2023 Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. Cannabis Cannabinoid Res · PMID 37721989 · DOI	Animal research animal	Sprague Dawley rats	THCV (also CBC, CBN, delta-8-THC) by oral gavage in oil THCV 3.2, 10, 17, 22, 32 or 100 mg/kg/day (rat amounts) 14 days · vs Vehicle (MCT oil)	No treatment-related deaths. The cannabinoids were generally well tolerated. Blood and tissue differences were judged biological variation, with no biologically significant tissue changes. Pain results across minor cannabinoids were inconsistent. The authors note modest dose-dependent trends in organ weights and blood chemistry that warrant study at higher amounts. Methods, limits and funding Outcomes: Behavior, weight, blood tests, organ weights, tissue pathology, pain sensitivity Limitations: Short, rat study; four compounds, many dose groups. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Levin 2010 Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend · PMID 19733018 · DOI	Rct secondary analysis	117 117 cannabis-dependent patients in a dronabinol trial	Smoked cannabis (own supply); the trial drug was dronabinol or placebo Trial period · vs Dronabinol vs placebo trial	All 117 patients had a positive urine test for the THC metabolite, but 50% had an undetectable THCV-COOH (under 1 ng/mL). The authors say THCV testing may not be sensitive enough to detect all marijuana use and may not separate marijuana from oral THC medicine. 50% of 117 patients had no detectable THCV-COOH. Methods, limits and funding Outcomes: Whether urine THCV-COOH shows recent marijuana use Limitations: The authors suggest the variety of cannabis smoked in the community may explain it; not an effects study. Funding and conflicts: NIDA (US) grants listed; no conflict listed. Read: abstract
LoParco 2025 Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. J Psychoactive Drugs · PMID 40131178 · DOI	Cross sectional web review web-review	The 20 most-visited online retailers found by searching "buy delta thc" in May 2023	Derived intoxicating cannabis products including THCV	On 18 of 20 sites with descriptions, all derived products except THCA and HHC-O were described as psychoactive or intoxicating. Twelve sites mentioned compounds "suitable for new users" (delta-8, delta-9 and delta-10 THC, HHC, THCP and THCV). The authors call some of the information potentially misleading and ask for stricter oversight and health warnings. Methods, limits and funding Outcomes: Marketing claims about each compound Limitations: Describes retailer marketing, not product contents. Funding and conflicts: NIDA grants listed; conflicts of interest: none declared. Read: abstract
McPartland 2015 Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol · PMID 25257544 · DOI	Systematic review review	In vitro and ex vivo mechanism studies of CBD and THCV, with animal and human studies interpreted	CBD and delta-9-THCV	Concludes CBD and THCV are not rimonabant-like and appear unlikely to cause the same unwanted brain effects. THCV is a high-affinity CB1 ligand and potent antagonist in vitro, yet only occasionally produces effects in animals that come from CB1 blocking; it also binds CB2 with high affinity and signals as a partial agonist. In vitro results do not always predict effects in vivo. Methods, limits and funding Outcomes: Whether CBD and THCV act like rimonabant (a withdrawn CB1 blocker) Limitations: Reviews mostly lab studies; the human trials interpreted were few and small. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Mendoza 2025 The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. AIMS Neurosci · PMID 40270953 · DOI	Narrative review review	Preclinical and early human studies of THCV in obesity and diabetes	THCV	Says animal and cell work shows THCV improves insulin sensitivity and glucose handling and may suppress appetite, and that "preliminary human trials" support this but larger trials are needed. Notes formulations and regulatory hurdles. Methods, limits and funding Outcomes: THCV in diabetes and weight management Limitations: A narrative review by a single author; selection of studies not described in the abstract. Funding and conflicts: No conflicts declared. Read: abstract
Pertwee 2008 The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol · PMID 17828291 · DOI	Review review	Lab and animal literature on three plant cannabinoids	THC, CBD and delta-9-THCV	Says delta-9-THCV is a potent CB2 partial agonist in vitro, antagonises cannabinoid agonists in CB1 tissues in a tissue- and ligand-dependent way, and in living animals acts as a CB1 antagonist or, at higher doses, as a CB1 agonist. Methods, limits and funding Outcomes: How THC, CBD and THCV act at CB1 and CB2 Limitations: A 2008 review; much newer work exists. Funding and conflicts: US NIH (NIDA) grants listed; no conflict listed. Read: abstract
Peters 2023 A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ(8)-Tetrahydrocannabivarin in Healthy Participants. Cannabis Cannabinoid Res · PMID 37721990 · DOI	Rct crossover	21 21 healthy adults (3 in an open ascending-dose first part, 18 in a double-blind crossover second part)	Delta-8-THCV (a man-made isomer, not the plant form) in oil, by mouth Single doses of 12.5, 25, 50, 100 and 200 mg (study amounts, not advice) Single doses, assessed to 8 hours · vs Placebo	Most adverse events (55 of 60) were mild; euphoric mood was the most common. The 12.5, 25 and 200 mg amounts gave faster times on a vigilance test, not dose-dependent. At 100 and 200 mg people rated "feel a drug effect" and "like the drug effect" higher. Almost all urine drug screens (78 of 79) 8 hours after an active dose were positive for THC. The authors write that THC-like effects at higher amounts were mild and not linked to impairment. THC-like effects appeared only at 100 and 200 mg of delta-8-THCV; urine THC screens were positive after almost all active doses. Methods, limits and funding Outcomes: Safety, adverse events, subjective and cognitive effects, urine drug screens Limitations: Small, single doses, healthy adults; the isomer tested (delta-8) is not the form found in cannabis plants, and the authors say how it carries over to delta-9-THCV is unclear. Funding and conflicts: Funded by Canopy Growth Corporation; several authors were Canopy employees at the time (stated in the companion pharmacokinetics paper). Registered NCT05210634. Read: abstract
Poceviciute 2026 Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. Sci Rep · PMID 42151379 · DOI	Animal research animal	Male rats with knee joint inflammation (CFA injection)	THCV, CBN or CBD vs ibuprofen Four daily doses (amounts not in the abstract) 4 days · vs Vehicle; ibuprofen	All three phytocannabinoids reduced mechanical hyperalgesia with little or no effect on activity. CBN and THCV recovered the body weight of the CFA-injected rats. CBD reduced body weight and raised some white-blood-cell counts. Methods, limits and funding Outcomes: Mechanical and thermal pain sensitivity, activity, weight, blood cells Limitations: Rat model; short. Funding and conflicts: Public research funders listed; authors declare no competing interests. Read: abstract
Poceviciute 2026 Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. Alcohol Alcohol · PMID 41947574 · DOI	Animal research animal	Male Wistar rats with long-term voluntary alcohol drinking	THCV, CBN or CBD by injection Once daily for three days (amounts not in the abstract) 3 days · vs Vehicle	CBN and THCV reduced alcohol intake and preference and had a mild sedative effect. CBD had a minor effect on intake. None caused discomfort or distress. Methods, limits and funding Outcomes: Alcohol intake and preference; water intake, weight, activity, distress calls Limitations: Rat drinking model; three days only; not people with alcohol use disorder. Funding and conflicts: Authors declare no conflict of interest. Read: abstract
Rao 2023 Comparative metabolism of THCA and THCV using UHPLC-Q-Exactive Orbitrap-MS. Xenobiotica · PMID 36951512 · DOI	Lab in-vitro	Human and mouse liver microsomes; mouse liver cells	THCA and delta-9-THCV	Found 29 metabolites in all. The abstract reports that THCV was transformed into THC and CBD in these systems, which conflicts with a review that says no known reaction converts between THC and THCV; treat this lab claim as unconfirmed. Also reports anti-inflammatory activity in mouse macrophage cells. Methods, limits and funding Outcomes: Metabolites and anti-inflammatory activity Limitations: Liver preparations and cells; one claim in the abstract is surprising and was not checked against the full text. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Riedel 2009 Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol · PMID 19378378 · DOI	Animal research animal	Mice, fasted and free-feeding	Pure delta-9-THCV and a THCV-rich cannabis extract Pure THCV at doses as low as 3 mg/kg (mouse amounts) Single and repeated days · vs Vehicle and a CB1 antagonist (AM251)	Pure THCV reduced food intake and weight at doses as low as 3 mg/kg, with no rebound the next day. A THCV-rich cannabis extract failed to reduce intake or weight, possibly because of leftover THC; adding CBD overcame the THC effect. Methods, limits and funding Outcomes: Food intake and body weight Limitations: Mice only; pure compound and extract behaved differently. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Rzepa 2015 The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. Int J Neuropsychopharmacol · PMID 26362774 · DOI	Rct crossover	20 20 healthy volunteers	THCV by mouth Single 10 mg dose (study amount, not advice) One dose per session · vs Placebo	No significant difference in subjective experience. THCV reduced connectivity between the amygdala and the default mode network and increased connectivity between the amygdala and the dorsal anterior cingulate cortex, and between the dorsomedial prefrontal cortex and the inferior frontal gyrus. Brain-scan differences with no change in how people felt. Methods, limits and funding Outcomes: Resting-state brain connectivity (fMRI scan), mood and subjective experience Limitations: One dose in 20 healthy people. Scan patterns are not a treatment effect; the authors link them to obesity only as a possibility. Funding and conflicts: No funder or conflict listed in the PubMed record. Read: abstract
Sempio 2024 Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants. Pharmaceuticals (Basel) · PMID 39770444 · DOI	Rct crossover	21 21 healthy participants enrolled; blood samples from 15 analysed	Delta-8-THCV in medium-chain triglyceride oil, by mouth Single doses of 12.5, 25, 50, 100 and 200 mg (study amounts, not advice) Blood samples up to 8 hours · vs Placebo	The main blood metabolite was 11-nor-9-carboxy-delta-8-THCV. Median time to peak was 3.8 to 5.0 hours for delta-8-THCV. Peak level and total exposure rose in step with dose; each doubling of dose raised total exposure 2.3- to 4.8-fold. Delta-9-THCV and its metabolite were found in plasma although a third-party lab did not detect delta-9-THCV in the product; the authors call this possible conversion and say it needs study. Dose-linear exposure; unexplained appearance of the delta-9 isomer in blood. Methods, limits and funding Outcomes: Pharmacokinetics of delta-8-THCV and its metabolites Limitations: Delta-8 isomer, healthy adults, up to 8 hours only, so no half-life; funded by the product maker. Funding and conflicts: Funded by Canopy Growth Corporation; authors include current and former Canopy employees; the funder had no role in analysis or interpretation, the paper says. Read: full-text
Sempio 2026 Metabolite patterns in human urine after oral administration of highly purified Δ8-THCV. Forensic Toxicol · PMID 42250012 · DOI	Rct crossover	Urine from healthy participants in the delta-8-THCV trial (80 pooled 0-8 hour samples)	Delta-8-THCV by mouth Same single doses as the trial (study amounts, not advice) 0 to 8 hours after dosing · vs Placebo (pre-dose samples)	The main urine metabolite was 11-nor-9-carboxy-delta-8-THCV, plus 11-hydroxy-delta-8-THCV and a delta-9-THCV acid metabolite, all heavily glucuronidated. Of 80 pooled samples, 70 were reported positive by a THC immunoassay although the samples were negative for the THC metabolite on the confirmation test. The authors conclude these metabolites cross-react and give false-positive results for THC use. 70 of 80 samples read positive on the THC screen, but were negative for the THC metabolite on LC-MS/MS. Methods, limits and funding Outcomes: Urine metabolites and cross-reaction with a THC urine test Limitations: One trial, one product, healthy adults, first 8 hours only. Funding and conflicts: Funded by Canopy Growth Corporation; several authors were Canopy employees with stock options at the time. Read: abstract
Shirakura 2026 Emerging cannabinoids differ in behavioral safety margins in mice: a comparative hazard proximity analysis of locomotor suppression and catalepsy-like immobility. Forensic Toxicol · PMID 42734683 · DOI	Animal research animal	Male C57BL/6J mice	THC, THCV, HHC and other cannabinoids by injection Not given in the abstract Acute · vs Vehicle	All cannabinoids reduced spontaneous movement. THCV increased immobility only at higher doses and did not reach 50% catalepsy in the range tested, so no hazard index was calculated for it; THC, THCH, HHCH and HHCP produced strong catalepsy-like immobility. Methods, limits and funding Outcomes: Reduced movement and catalepsy-like immobility Limitations: Mice; single injections; forensic-screening purpose. Funding and conflicts: Authors declare no competing interests. Read: abstract
Smith 2025 Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips. Cannabis · PMID 39968488 · DOI	Controlled trial combination product	44 44 adults (31 women, 13 men), average age 51.75	Mouthstrips (mucoadhesive) with THCV plus CBD THCV 8 mg + CBD 10 mg, or THCV 16 mg + CBD 20 mg, once daily (study amounts, not advice) 90 days · vs Placebo	The THCV plus CBD strips were linked to statistically significant weight loss and smaller waist, systolic blood pressure, total and LDL cholesterol. The higher strength was better for weight loss. The author notes small groups in the higher-strength and placebo arms. Both strengths differed from placebo; higher strength better for weight loss. Numbers are not in the abstract. Methods, limits and funding Outcomes: Weight, waist, blood pressure, cholesterol Limitations: A THCV plus CBD combination, so any effect cannot be assigned to THCV alone; small groups; the abstract does not say how people were assigned, how many were in each arm, or give the actual numbers. The paper links its results to "prior unpublished studies" of a hemp extract. Funding and conflicts: Single author affiliated with NeX Therapeutics (PubMed record); no conflict declared in the paper. Company ties to the strip product were not stated in the abstract. Read: abstract
Stone 2020 A systematic review of minor phytocannabinoids with promising neuroprotective potential. Br J Pharmacol · PMID 32608035 · DOI	Systematic review review	31 articles on minor cannabinoids and neuroprotection (mostly animal and lab)	Minor cannabinoids including THCV THCV 0.025 to 2.5 mg/kg in animal models	Says THCV (0.025 to 2.5 mg/kg in animals) showed promise in models of seizure and hypomobility, Huntington's and Parkinson's disease. All the evidence was from animals and cells. Methods, limits and funding Outcomes: Neuroprotective effects in models of disease Limitations: Abstract gives no human data; THCV is one of many compounds covered. Funding and conflicts: One author owns a cannabis consulting company and advises Artelo Biosciences; others declare none. Read: abstract
Tudge 2014 Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. Int J Neuropsychopharmacol · PMID 25542687 · DOI	Rct crossover	20 20 healthy volunteers	THCV by mouth Single 10 mg dose (study amount, not advice) One dose per session · vs Placebo	No significant differences in ratings. THCV increased brain responses to chocolate in the midbrain, anterior cingulate cortex, caudate and putamen, and increased responses to aversive stimuli in the amygdala, insula, mid orbitofrontal cortex, caudate and putamen. Larger brain responses to both pleasant and unpleasant food cues; no change in ratings. Methods, limits and funding Outcomes: Brain responses (fMRI) to chocolate (reward) and to moldy strawberry pictures or taste (aversive); pleasantness, intensity and wanting ratings Limitations: One dose, 20 healthy people, no weight or eating outcome. The authors suggest a possible use in obesity; the study does not test that. Funding and conflicts: Medical Research Council listed as funder in PubMed; no conflict listed. Read: abstract
UK Parliament / legislation.gov.uk 2026 Misuse of Drugs Act 1971, Schedule 2 (legislation.gov.uk) legislation.gov.uk · Source	Authoritative guidance n/a	n/a	n/a	Class B of the schedule lists "Cannabinol", "Cannabinol derivatives" and "Cannabis and cannabis resin". The Act defines "cannabinol derivatives", except where contained in cannabis or cannabis resin, as tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives. The page does not name THCV. Methods, limits and funding Outcomes: UK listing of cannabinol and cannabinol derivatives Limitations: The page does not say whether THCV falls inside the definition; a 2025 laboratory paper (PMID 39832132) calls THCV a UK controlled cannabinoid. Not legal advice. Read: full-text
US Food and Drug Administration 2024 FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Questions and Answers FDA website · Source	Authoritative guidance n/a	n/a	n/a	Says the FDA has not approved a marketing application for cannabis for any disease or condition, and has approved one cannabis-derived and three cannabis-related drug products, available only by prescription. A text search of the page found no mention of THCV or tetrahydrocannabivarin. Methods, limits and funding Outcomes: US regulator statements on approved products Limitations: A general page on cannabis and CBD; content current as of 07/16/2024; later changes were not checked. Read: full-text
US National Library of Medicine 2026 PubChem compound record: Tetrahydrocannabinol (CID 16078) PubChem · Source	Reference database n/a	n/a	n/a	Retrieved through the PubChem REST API on 2026-10-25: formula C21H30O2, title Tetrahydrocannabinol. Methods, limits and funding Outcomes: Chemical identity Limitations: A database record, not a study. Read: full-text
US National Library of Medicine 2026 PubChem compound record: Tetrahydrocannabivarinic acid (CID 59444416) PubChem · Source	Reference database n/a	n/a	n/a	Retrieved through the PubChem REST API on 2026-10-25: formula C20H26O4, title Tetrahydrocannabivarinic acid. Methods, limits and funding Outcomes: Chemical identity Limitations: A database record, not a study. Read: full-text
US National Library of Medicine 2026 PubChem compound record: Cannabidivarin (CID 11601669) PubChem · Source	Reference database n/a	n/a	n/a	Retrieved through the PubChem REST API on 2026-10-25: formula C19H26O2, title Cannabidivarin. Methods, limits and funding Outcomes: Chemical identity Limitations: A database record, not a study. Read: full-text
US National Library of Medicine 2026 PubChem compound record: Tetrahydrocannabivarin (CID 93147) PubChem · Source	Reference database n/a	n/a	n/a	Retrieved through the PubChem REST API on 2026-10-25: formula C19H26O2, molecular weight 286.4, InChIKey ZROLHBHDLIHEMS-HUUCEWRRSA-N, CAS 31262-37-0 in the synonym list. Methods, limits and funding Outcomes: Chemical identity Limitations: A database record, not a study. Read: full-text
Wargent 2013 The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes · PMID 23712280 · DOI	Animal research animal	Mice fed a high-fat diet (diet-induced obesity) and genetically obese ob/ob mice; insulin-resistant liver and muscle cells	THCV by mouth 0.1 to 12.5 mg/kg daily or twice daily in mice (not human amounts) 30 to 45 days · vs Vehicle and a CB1 inverse agonist (AM251)	THCV did not significantly change food intake or weight gain in any of the studies. It gave a brief rise in energy use, lowered glucose intolerance in ob/ob mice in a dose-dependent way, improved glucose tolerance and insulin sensitivity in diet-induced obese mice without consistent effects on blood fats, and restored insulin signalling in insulin-resistant liver and muscle cells. Methods, limits and funding Outcomes: Food intake, weight, energy use, glucose tolerance, insulin, blood fats, liver fat Limitations: Mouse and cell work; the earlier hypothesis that THCV cuts appetite was not supported here. Funding and conflicts: Funding and conflicts were not stated in the PubMed record read. Read: abstract
Wiley 2024 Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice. Prog Neuropsychopharmacol Biol Psychiatry · PMID 38417478 · DOI	Animal research animal	Mice trained to discriminate THC; receptor binding assays	Several minor cannabinoids including delta-9-THCV, and terpenes Not given in the abstract Acute · vs Vehicle	All minor cannabinoids showed measurable CB1 and CB2 binding. Only delta-8-THC fully replaced THC; CBN and delta-10-THC partly did. THCV did not alter the THC-like effect in mice. Methods, limits and funding Outcomes: THC-like effects and CB1/CB2 binding Limitations: Mice; abstract does not give THCV amounts tested. Funding and conflicts: US NIH grants listed; authors declare no competing interests. Read: abstract

What we do not know yet

What the evidence supports: nothing at high certainty. The best human evidence is a few small studies, rated low or very low, and several are tied to cannabis companies.
No independent repeat of the diabetes trial, and no trial of THCV alone for weight.
No human trial of delta-9-THCV above about 10 mg, so the amount at which the plant form starts to feel like THC is unknown.
No study has tested whether THCV-labelled products match their labels or say which form they hold.
No data on interactions with medicines or alcohol, long-term safety, liver effects, driving, pregnancy, breastfeeding, children or older adults.

How new research is added

New studies are found by a saved PubMed search and are placed in a review queue. A person reads each one before it changes any evidence rating or safety wording.

Lab markers

What changed in blood or saliva tests during trials. A changed number is not the same as feeling or being healthier, and we give no "normal ranges".

Metabolic 1

●

HDL cholesterol (the trial's main target)

No clear change in trials

The so-called good cholesterol in the blood.

Very low certainty

Results and what it means

Why it was measured

It was the main target of the type 2 diabetes trial.

Statistical vs. clinical meaning

The trial missed its main target.

Safety implication

None stated.

Study	Result	People	Product
¹³	Plasma HDL was unaffected by THCV (the abstract says so; apolipoprotein A did change).	62 adults with type 2 diabetes	THCV 5 mg twice daily for 13 weeks

¹³

Other 15

▼

Fasting blood glucose

Lowered in trials

Blood sugar measured after not eating overnight.

Very low certainty

Results and what it means

Why it was measured

A key measure of blood sugar control in type 2 diabetes.

Statistical vs. clinical meaning

One small human trial plus mouse work, with the main trial target missed.

Safety implication

A glucose-lowering effect matters for people who take diabetes medicines.

Study	Result	People	Product
¹³	THCV alone lowered fasting plasma glucose against placebo (difference -1.2 mmol/L; P<0.05). The CBD and mixture groups did not differ from placebo.	62 adults with type 2 diabetes	THCV 5 mg twice daily for 13 weeks versus placebo
⁴⁰	In mice, THCV improved glucose tolerance and insulin sensitivity (dose-dependent in ob/ob mice).	Obese mice	Oral THCV for 30 to 45 days

^{13 40}

●

Beta-cell function (HOMA2)

Improved in trials

A calculated score of how well the pancreas's insulin-making cells work.

Very low certainty

Results and what it means

Why it was measured

A secondary measure in the type 2 diabetes trial.

Statistical vs. clinical meaning

A secondary result among many; not confirmed elsewhere.

Safety implication

No safety implication stated.

Study	Result	People	Product
¹³	THCV alone versus placebo: HOMA2 beta-cell function difference -44.51 points (P<0.01), reported as an improvement. The sign is as printed in the abstract.	62 adults with type 2 diabetes	THCV 5 mg twice daily for 13 weeks

¹³

▼

Body weight and waist size

Lowered in trials

Weight and abdominal girth.

Not enough evidence

Results and what it means

Why it was measured

Main outcomes of the THCV plus CBD strip study; secondary in the diabetes trial.

Statistical vs. clinical meaning

The human result is for a combination; mouse results disagree.

Safety implication

No safety data in the abstract.

Study	Result	People	Product
³¹	Both strengths of THCV plus CBD strips were linked to weight loss and smaller waist against placebo, with the higher strength better; the abstract gives no numbers.	44 adults	THCV 8 mg + CBD 10 mg, or 16 mg + 20 mg, daily for 90 days
⁴⁰	In mice, THCV did not significantly change food intake or weight gain.	Obese mice	Oral THCV for 30 to 45 days
²⁶	In free-feeding mice, pure THCV reduced food intake and weight at 3 mg/kg.	Mice	Pure THCV, single and repeated doses

^{31 40 26}

▲

Brain response to food cues (fMRI)

Raised in trials

Blood-flow changes in brain areas when people see or taste pleasant or unpleasant food.

Not enough evidence

Results and what it means

Why it was measured

To test whether THCV changes reward and aversion signals.

Statistical vs. clinical meaning

Brain activity changes with no change in how people felt; not a health outcome.

Safety implication

None stated.

Study	Result	People	Product
³³	THCV increased responses to chocolate in the midbrain, anterior cingulate, caudate and putamen, and to aversive stimuli in the amygdala, insula, mid orbitofrontal cortex, caudate and putamen. No difference in ratings.	20 healthy volunteers	Single 10 mg dose versus placebo

³³

↕

Resting brain connectivity (default mode network)

Mixed results in trials

How strongly brain regions' activity moves together at rest.

Not enough evidence

Results and what it means

Why it was measured

To see how THCV changes brain networks tied to emotion and control.

Statistical vs. clinical meaning

Scan differences without any health outcome.

Safety implication

None stated.

Study	Result	People	Product
²⁷	THCV reduced connectivity between the amygdala and the default mode network and raised connectivity between the amygdala and the dorsal anterior cingulate cortex, and between the dorsomedial prefrontal cortex and the inferior frontal gyrus. Subjective experience did not differ.	20 healthy volunteers	Single 10 mg dose versus placebo

²⁷

▼

Heart rate rise after THC

Lowered in trials

The increase in pulse that follows an intravenous THC dose.

Very low certainty

Results and what it means

Why it was measured

A physical sign of THC's effect used to test whether THCV blocks THC.

Statistical vs. clinical meaning

One of several outcomes in a 10-person pilot.

Safety implication

Not a sign that THCV makes THC safe.

Study	Result	People	Product
⁶	Five days of THCV 10 mg inhibited the THC-induced rise in heart rate (Z=-2.193, p=0.028).	10 healthy men	THCV 10 mg daily for 5 days, then THC 1 mg by vein

⁶

↕

Delayed word recall and memory intrusions after THC

Mixed results in trials

Remembering words after a delay, and false recalled words (intrusions).

Very low certainty

Results and what it means

Why it was measured

Memory impairment is a common THC effect; the pilot tested whether THCV protects against it.

Statistical vs. clinical meaning

One effect blocked, another increased; tiny sample.

Safety implication

Memory intrusions rose with THCV plus THC.

Study	Result	People	Product
⁶	Delayed verbal recall was impaired by THC only under placebo (Z=-2.201, p=0.028), suggesting a protective effect of THCV. Memory intrusions were significantly higher with THC plus THCV (Z=-2.155, p=0.031).	10 healthy men	THCV 10 mg daily for 5 days, then THC 1 mg by vein

⁶

▲

Rating: "feel a drug effect" and "like the drug effect"

Raised in trials

Volunteers' own rating of whether they feel the substance.

Low certainty

Results and what it means

Why it was measured

To test whether THCV, or a close isomer, produces THC-like feelings.

Statistical vs. clinical meaning

Effect depends on amount and on which isomer was used.

Safety implication

Higher amounts can produce THC-like effects.

Study	Result	People	Product
²²	At 100 and 200 mg of delta-8-THCV, ratings of feeling a drug effect and liking it were higher than placebo; lower amounts (12.5 to 50 mg) did not show THC-like subjective effects.	21 healthy adults	Single oral delta-8-THCV doses versus placebo
⁶	10 mg of delta-9-THCV was subjectively indistinguishable from placebo.	10 healthy men	THCV 10 mg daily for 5 days

^{22 6}

▲

Urine THC drug screen result

Raised in trials

Whether a urine immunoassay reports THC use.

Low certainty

Results and what it means

Why it was measured

Drug-testing programs use these screens, and THCV metabolites resemble THC metabolites.

Statistical vs. clinical meaning

Two reports from the same trial agree that most samples read positive; confirmation testing can tell the difference.

Safety implication

A THCV product can cause a positive THC screen. Matters for work and sport testing.

Study	Result	People	Product
²²	Almost all urine drug screens (78 of 79) 8 hours after an active delta-8-THCV dose were positive for THC.	21 healthy adults	Single oral delta-8-THCV doses
²⁹	Of 80 pooled urine samples, 70 read positive on a THC immunoassay although negative for the THC metabolite on LC-MS/MS testing.	Same trial	Delta-8-THCV doses

^{22 29}

●

Seizure incidence in rats

Lowered (in rats) in trials

How often rats given a seizure-causing drug (PTZ) have a seizure.

Not enough evidence

Results and what it means

Why it was measured

A standard test for medicines that might reduce seizures.

Statistical vs. clinical meaning

Animal result only.

Safety implication

None stated.

Study	Result	People	Product
¹²	THCV at 0.25 mg/kg significantly reduced seizure incidence in PTZ-treated rats.	Adult rats	THCV by injection, 0.025 to 2.5 mg/kg tested

¹²

●

Loss of dopamine-making nerve cells (TH-positive neurons)

Lowered (in animals) in trials

Count of tyrosine-hydroxylase-positive nerve cells in the substantia nigra, which are lost in Parkinson's disease.

Not enough evidence

Results and what it means

Why it was measured

A standard marker of damage in Parkinson's disease models.

Statistical vs. clinical meaning

Two rodent models; no human data.

Safety implication

None stated.

Study	Result	People	Product
⁸	Chronic THCV attenuated the loss of tyrosine-hydroxylase-positive neurones caused by 6-hydroxydopamine in rats and by LPS in mice.	Lesioned rats and mice	THCV by injection

⁸

●

Abnormal involuntary movements after L-DOPA (mice)

Lowered (in mice) in trials

Time mice spend in abnormal movements, the model of L-DOPA dyskinesia.

Not enough evidence

Results and what it means

Why it was measured

Measures the movement side effect of Parkinson's treatment in a mouse model.

Statistical vs. clinical meaning

One mouse model.

Safety implication

None stated.

Study	Result	People	Product
⁷	THCV (2 mg/kg for two weeks) delayed the appearance of the signs and decreased their intensity, with lower FosB and pAcH3 in brain tissue; it also reduced intensity when started after signs were present.	Pitx3ak mutant mice	THCV with L-DOPA

⁷

●

Pain sensitivity and paw swelling (rodents)

Lowered (in animals) in trials

How strongly mice or rats react to touch or heat, and swelling after an inflammatory injection.

Not enough evidence

Results and what it means

Why it was measured

Standard measures in pain and inflammation models.

Statistical vs. clinical meaning

Two species point the same way; no human data.

Safety implication

None stated.

Study	Result	People	Product
¹	THCV 0.3 or 1 mg/kg decreased carrageenan swelling and suppressed carrageenan-induced hyperalgesia; it decreased pain behaviour in the formalin test at 1 mg/kg and at 5 mg/kg.	Mice	THCV by injection
²³	THCV reduced mechanical hyperalgesia in rats with knee inflammation, with little or no effect on activity.	Male rats	Four daily THCV doses versus ibuprofen

^{1 23}

●

Voluntary alcohol intake (rats)

Lowered (in rats) in trials

How much alcohol rats choose to drink when offered it.

Not enough evidence

Results and what it means

Why it was measured

A model of alcohol use disorder.

Statistical vs. clinical meaning

One short rat study.

Safety implication

Mild sedation seen.

Study	Result	People	Product
²⁴	THCV reduced alcohol intake and alcohol preference and had a mild sedative effect.	Male Wistar rats	Three once-daily THCV doses

²⁴

●

Inflammation markers in human macrophage cells

Lowered (in cells) in trials

Levels of inflammation-pathway proteins in cells treated with an inflammatory trigger.

Not enough evidence

Results and what it means

Why it was measured

To test how THCV might lower inflammation at the cell level.

Statistical vs. clinical meaning

Cells in a dish.

Safety implication

None stated.

Study	Result	People	Product
⁹	THCV reduced markers of the NLRP3 inflammasome pathway (PANX1/P2X7), the IL-6/TYK-2/STAT-3 pathway and NF-kB activity.	THP-1 macrophage cells	THCV before LPS and ATP

⁹

Safety

What studies and official sources say about side effects, medicines and who should check first. Each point shows what kind of evidence it comes from.

Main points to know 9

No THCV medicine is approved, and the FDA page does not mention THCV. The FDA says it has not approved a marketing application for cannabis for any disease or condition. It has approved one cannabis-derived and three cannabis-related prescription drug products; THCV is not named. A text search of the FDA page found no mention of THCV. Products sold as THCV are not approved medicines. Authoritative guidance ³⁵
Short human studies found mostly mild effects, but they were small, short and often company-linked. A 13-week trial in 62 adults with type 2 diabetes said THCV was well tolerated. Ten men took THCV for five days with no difference from placebo. In a 21-person trial of the man-made delta-8 form, 55 of 60 adverse events were mild and euphoric mood was the most common. The delta-8 trial, and a review arguing that THCV is not THC, were written by people tied to cannabis companies. Nothing is known about long-term use. Controlled trial ^{13 6 22 10}
Higher amounts can feel like THC, and the effect depends on the amount. At about 10 mg by mouth, small studies found delta-9-THCV could not be told from placebo. At 100 and 200 mg of delta-8-THCV, volunteers rated feeling and liking a drug effect. In rats, THCV partly mimicked THC at one amount and blocked a low THC amount at another. Reviews say THCV can act as a blocker at some amounts and a weak agonist at higher ones. Sources do not tell readers how much is safe. Controlled trial ^{22 6 15 21 10}
THCV did not make THC safe: it blocked some THC effects and increased another. In a 10-man pilot, five days of THCV cut the THC rise in heart rate and delayed word-recall problems, and made THC feel weaker, but increased memory intrusions. THC was given by vein at a small amount. Nothing in this supports using THCV to offset cannabis. The effect may differ for smoked or swallowed THC. Controlled trial ⁶
Can cause a positive urine drug screen for THC. After active delta-8-THCV doses, 78 of 79 urine screens were positive for THC in one report, and 70 of 80 pooled samples read positive on a THC immunoassay in another, although the THC metabolite test was negative. Both reports come from the same trial. Confirmation testing can tell the difference, but a first screen may not. Controlled trial ^{22 29}
Labels and forms are unreliable: delta-9 versus delta-8, and what is really in the product. THCV comes as delta-9-THCV (the plant form) and delta-8-THCV, which a review says is semi-synthetic and has not been reported in cannabis plants. A label that says only "THCV" may not say which. In a trial, delta-9-THCV appeared in blood although a third-party lab had not found it in the delta-8 product. We found no study that tested whether products sold as THCV match their labels. Review ^{10 28}
A glucose-lowering effect can matter for people on diabetes medicines. In the 13-week diabetes trial, THCV alone lowered fasting blood glucose against placebo. No study tested THCV together with diabetes medicines, so interactions are unknown. A doctor or pharmacist should know about any THCV product if you take medicine for blood sugar. Controlled trial ¹³
No data in pregnancy, breastfeeding, children, older adults, or liver disease. No study in these groups was found. The FDA page says it is aware of potential adverse health effects of THC-containing cannabis products in pregnant or lactating women. Products labelled THCV may also hold THC. Gap ³⁵
The legal picture is changing and differs by country. US federal law is changing the hemp definition, with most parts due December 11, 2026; the summary read does not name THCV. The UK Misuse of Drugs Act schedule lists cannabinol and cannabinol derivatives in Class B but does not name THCV; a 2025 laboratory paper calls THCV a UK controlled cannabinoid. This is not legal advice; ask a lawyer or the local regulator. Authoritative guidance ^{3 34 11}

Side effects 5

Effect	How often	Severity and recovery	Evidence
Euphoric mood, mild Delta-8 form, single doses of 12.5 to 200 mg; higher amounts raised ratings of feeling a drug effect.	The most common adverse event in the delta-8-THCV trial; 55 of 60 adverse events overall were mild	mild Not stated in the abstract	Controlled trial ²²
Memory intrusions when taken with THC A tiny pilot; many outcomes tested.	Significantly increased in the 10-man pilot (Z=-2.155, p=0.031)	mild Not stated	Controlled trial ⁶
General tolerability in diabetes and healthy volunteers Counts of side effects are not given in the abstracts.	"Well tolerated" in the 13-week trial; no problems with 10 mg for 5 days; no adverse event data in the brain-scan abstracts	mild Not stated	Controlled trial ^{13 6 33 27}
Mild sedation in rats Animal finding; sedation in people has not been measured.	Seen with THCV in the alcohol-drinking rat study	mild Not stated	Animal research ²⁴
Reduced movement and, at higher doses, immobility in mice Mouse injections; not human amounts.	THCV increased immobility only at higher doses and did not reach 50% catalepsy in the range tested	not applicable Not stated	Animal research ³⁰

Liver

No human data on liver effects of THCV were found. In rats given THCV for 14 days (up to 100 mg per kg per day) the authors report no biologically significant tissue changes, with modest dose-dependent trends in organ weights and blood chemistry that they say warrant study at higher amounts. In human and mouse liver preparations, THCV was changed into many metabolites. One abstract reports that this included THC and CBD, which is unconfirmed and in conflict with a review stating no known reaction turns THCV into THC. The abstracts of the human trials read do not report liver test results; the 13-week diabetes trial listed liver fat as a measure but the abstract gives no result. ^{16 25 10 13}

How often. No rates of liver injury are known for THCV in people. We did not find a LiverTox entry for THCV and did not check one.

Monitoring. No regulator guidance on liver tests for THCV was found. Anyone with liver disease or taking medicines that affect the liver should ask a doctor or pharmacist before using a THCV product.

This is a safety connection. It is not evidence that THCV (Tetrahydrocannabivarin) supports liver health.

Medicines and supplements 5

With	Why it matters	Importance	Evidence	What to do
THC and cannabis supplement	THCV competes with THC at the CB1 receptor. In a pilot, THCV weakened some THC effects and increased memory intrusions. In rats, THCV partly mimicked THC at one amount and blocked it at another.	Unknown for real-world cannabis. The pilot used intravenous THC at a small amount.	Controlled trial Very low certainty ^{6 15 10}	Do not assume THCV makes THC safer. Ask a doctor or pharmacist.
Diabetes medicines (including insulin) prescription	THCV lowered fasting blood glucose in a 13-week trial in adults with type 2 diabetes who did not use insulin.	Unknown; no study combined THCV with diabetes medicines, and low blood sugar has not been studied.	Controlled trial Very low certainty ¹³	Ask a doctor or pharmacist before using THCV if you take medicine for blood sugar.
Alcohol and sedating medicines supplement	THCV reduced alcohol intake and had a mild sedative effect in rats.	Unknown in people; no study combined THCV with alcohol or sedatives.	Animal research Not enough evidence ²⁴	Ask a pharmacist before combining a THCV product with alcohol or sedating medicines.
CBD supplement	In the diabetes trial the CBD plus THCV mixtures did not differ from placebo. In mice, adding CBD overcame the effect of leftover THC in a THCV-rich extract.	Unknown; the findings point in different directions.	Controlled trial Very low certainty ^{13 26}	No advice can be drawn from these results.
Medicines broken down by liver enzymes (CYP/UGT) prescription	No study of THCV and drug-metabolising enzymes in people was found; THCV is changed into hydroxy and carboxy metabolites in the liver.	Unknown; no interaction study.	Laboratory research Not enough evidence ^{25 28}	Ask a pharmacist before combining THCV with any prescription medicine.

Who should check first 9

Situation	Advice	Evidence
Pregnancy	No human safety data for THCV. The FDA says it is aware of potential adverse effects of THC-containing cannabis products in pregnant or lactating women, and THCV products may hold THC. Avoid unless a doctor advises otherwise.	Authoritative guidance ³⁵
Breastfeeding	No data on THCV in human milk. The FDA page raises potential harms of THC-containing cannabis in lactation. Talk to a doctor.	Authoritative guidance ³⁵
Children	No safety data. The FDA recommends keeping cannabis products out of reach of children to prevent accidental ingestion. Call a poison center if a child swallows a product.	Authoritative guidance ³⁵
Teens and young adults	No THCV data in this group. See the THC page for what is known about THC in young people. Products sold as THCV may hold THC.	Gap
Older adults	No study in older adults was found, and no analysis by age appears in the abstracts read. Ask a doctor, especially if you take several medicines.	Gap ^{13 31}
Mental health conditions (psychosis, anxiety, depression, cannabis use disorder)	No human trial of THCV in these conditions was found. Higher amounts of the delta-8 form gave THC-like effects. Products may hold THC, which is linked to psychosis risk and dependence. Ask a doctor.	Gap ^{22 2}
Driving, machinery and work that needs alertness	Driving was not tested. Euphoric mood and drug-effect ratings occurred at higher amounts of delta-8-THCV, and rats showed mild sedation. Wait to see how any product affects you and do not drive if impaired.	Controlled trial ^{22 24}
People using diabetes medicines	THCV lowered blood glucose in one trial. Ask a doctor or pharmacist before using it.	Controlled trial ¹³
People who are drug tested	THCV and its metabolites can cause a positive urine THC screen, even when confirmation tests are negative for THC. Ask the testing body before use.	Controlled trial ^{22 29 17}

Overdose, product quality and regulators

Summary. No toxic dose is established for people. Short human studies reported mostly mild effects. In rats given up to 100 mg per kg per day by mouth for 14 days, the compound was generally well tolerated, with no biologically significant tissue changes.

Animal. In a 14-day rat study (oral gavage in oil), THCV at 3.2 to 100 mg per kg per day produced no treatment-related deaths and no biologically significant tissue changes, with modest dose-dependent trends in organ weights and blood chemistry noted for further study. In mice, THCV reduced movement and caused immobility only at higher doses.

Human doses studied. Studied amounts in people: 5 mg twice daily for 13 weeks (diabetes trial); 10 mg daily for 5 days and single 10 mg doses (volunteer studies); 8 or 16 mg daily with CBD for 90 days (strip study); and single 12.5 to 200 mg of delta-8-THCV (21 adults). These are study amounts, not advice. A review by industry authors says most THCV consumer products contain under 5 mg.

High dose or long term signals. At 100 and 200 mg of delta-8-THCV, volunteers rated feeling and liking a drug effect. No long-term human data exist beyond 13 weeks (diabetes) and 90 days (strips).

Overdose response. Not studied. The highest single amount tested in people was 200 mg of delta-8-THCV, in a trial of 21 adults.

Genotoxicity. Not studied in the sources read.

Products sold as THCV are supplements, vapes, gummies or oils without the checks that apply to medicines. We found no test of whether products labelled THCV match their labels. The closest evidence is tests of CBD products and a review of retailer claims.

Minor cannabinoids in 80 over-the-counter CBD oils (Kentucky). Minor cannabinoids were present in many products and varied from trace amounts to several mg/mL. The authors say these amounts are largely absent from labels, leaving consumers uninformed. The abstract does not give a THCV-specific result. ¹⁴

UK CBD edibles and controlled cannabinoids. In 148 CBD edibles, 66% of the 135 with measurable CBD had detectable amounts of one or more UK-controlled cannabinoids; the paper names delta-9-THC, delta-8-THC, CBN and THCV among them. The abstract does not break out THCV. ¹¹

Delta-9 versus delta-8 THCV, and other isomers. A review says delta-8-THCV is semi-synthetic and has not been reported in cannabis plants, and that its manufacture can produce other THCV isomers whose activity is unknown and whose presence in products has not been studied. In one trial, delta-9-THCV and its metabolite appeared in blood even though a third-party lab had not detected it in the delta-8 product. ^{10 28}

How THCV is sold online. In a review of 20 online retailers, 12 mentioned compounds "suitable for new users", including THCV among a list of THC, HHC and THCP products. The authors call some marketing potentially misleading. ¹⁸

Accuracy of THCV-labelled products. No study testing whether THCV-labelled gummies, vapes, flower or capsules match their labels was found in the sources read.

Body	Action	Date
US Food and Drug Administration (United States)	Its cannabis Q&A page says the FDA has not approved a marketing application for cannabis for the treatment of any disease or condition, and has approved one cannabis-derived and three cannabis-related drug products, available only with a prescription. THCV is not named; a text search of the page found no mention of tetrahydrocannabivarin or THCV. source	2026-10-25
Congressional Research Service (US Congress) (United States)	Says a new law (P.L. 119-37) changes the hemp definition to total THC including THCA at no more than 0.3% dry weight, excludes hemp-derived cannabinoid products with cannabinoids that are not capable of being naturally produced by the plant or that were synthesized or manufactured outside the plant, and limits final products to 0.4 mg per container of total THC and other cannabinoids with similar effects. Most parts take effect December 11, 2026 (some November 12, 2026). The FDA lists of cannabinoids had not been published as of September 28, 2026. The summary does not name THCV, so how delta-9-THCV and delta-8-THCV products are treated is not stated. source	2026-10-25
UK Parliament (Misuse of Drugs Act 1971) (United Kingdom)	Schedule 2 lists "Cannabinol", "Cannabinol derivatives" and "Cannabis and cannabis resin" in Class B. The Act defines cannabinol derivatives, except where contained in cannabis or cannabis resin, as tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives. The page does not name THCV. A 2025 laboratory paper on CBD foods calls THCV one of the UK controlled cannabinoids it measured. source	2026-10-25

When to get medical help

A child has swallowed any THCV, hemp or cannabis product, or an adult took far more than intended: call a poison center or emergency number (in the US, 1-800-222-1222).
Very hard to wake, slow or shallow breathing, or confusion, especially after mixing with alcohol or sedating medicines: call emergency services.
Rash, swelling of the face, lips or throat, or trouble breathing: possible allergic reaction. Get emergency care.
Fast heartbeat, fainting, severe panic or seeing or hearing things that are not there after a product that may contain THC: get medical help.
Shaking, sweating, confusion or fainting if you take diabetes medicine (possible low blood sugar): check your blood sugar and get help.
Thoughts of suicide or self-harm, or new severe mood or behaviour changes: get urgent help.

Stop using the product and contact a clinician or emergency service. In the US, Poison Control is 1-800-222-1222.

General information only, not medical advice. Ask a clinician or pharmacist before use, especially with medicines, in pregnancy or with a health condition. See the Natural Remedy Safety guide.

Frequently asked questions

What is THCV?

THCV (tetrahydrocannabivarin) is a compound found in small amounts in some cannabis plants. It looks like THC but has a shorter side chain. It is not an approved medicine, and human research is a few small studies.

^{39 10 35}

Is THCV the same as THC?

No. A 2025 perspective says THCV is not an isomer of THC, is made by the plant from a different starting acid, and cannot be converted to or from THC by any known reaction. They share a ring structure but THCV has a three-carbon side chain, and in most studies it blocks the CB1 receptor that THC activates.

^{10 19 21}

Does THCV get you high?

It depends on the amount and the form. About 10 mg of delta-9-THCV could not be told from placebo in small studies. At 100 and 200 mg of the man-made delta-8 form, volunteers rated feeling and liking a drug effect, and euphoric mood was the most common mild side effect. No study tested delta-9-THCV at higher amounts. Products labelled THCV may also hold THC.

^{6 22 13 10}

Does THCV help with weight loss?

The evidence is thin. The only human weight result is from a 90-day study of mouth strips that combined THCV with CBD, whose abstract has no numbers. In mice, pure THCV cut food intake in one study and did not in another. Two brain-scan studies found no change in ratings of food. The "diet weed" nickname is ahead of the evidence.

^{31 26 40 33 10}

Does THCV help with type 2 diabetes?

One 13-week trial in 62 adults found THCV alone lowered fasting blood sugar compared with placebo, but it missed its main target (HDL cholesterol), used many secondary measures and has not been repeated. A doctor treats diabetes; do not stop or change medicine because of this.

^{13 20}

Can THCV block the effects of THC?

Partly, in one tiny pilot. In 10 men, five days of THCV cut the THC rise in heart rate and made THC feel weaker, but increased memory intrusions. THC was given by vein at a small amount. In rats, THCV blocked or mimicked THC depending on the amount. It should not be used to offset cannabis.

^{6 15 19}

What is the difference between delta-9 and delta-8 THCV?

Delta-9-THCV is the plant form. A review says delta-8-THCV has not been reported in cannabis plants and is probably semi-synthetic, made from CBDV. The highest-amount human trial used delta-8. The isomers differ in lab potency, and a labelled "THCV" product may be either.

^{10 22 28}

What are the side effects, and can I drive?

In short trials, side effects were mostly mild. Euphoric mood was the most common in the delta-8 trial, and the diabetes trial said THCV was well tolerated. Long-term effects are unknown. Driving was not tested, and higher amounts felt like a drug, so do not drive if you feel impaired.

^{22 13 24}

Will THCV show up on a drug test?

It can. After delta-8-THCV, 78 of 79 urine screens were positive for THC in one report, and 70 of 80 samples read positive on a THC screen in another though confirmation tests were negative for THC. Half of 117 patients in a different study had no detectable THCV metabolite after smoking cannabis, so THCV testing is not a reliable marker either way.

^{22 29 17}

Do THCV products contain what the label says?

We found no study that tested THCV-labelled products. Tests of CBD products show minor cannabinoids are often missing from labels, and a review says labels rarely say whether THCV is the delta-9 or delta-8 form. A batch certificate of analysis from an independent lab is the only way to know.

^{14 11 10}

Is THCV safe in pregnancy, breastfeeding, or for children?

No data exist. The FDA says it is aware of potential adverse health effects of THC-containing cannabis products in pregnant or lactating women, and THCV products may hold THC. The FDA recommends keeping cannabis products out of reach of children. Ask a doctor.

³⁵

Is THCV legal or approved?

No THCV medicine is approved by the FDA, and its cannabis Q&A page does not mention THCV. US hemp law is changing, with most parts due December 11, 2026, and the summary we read does not name THCV. The UK Misuse of Drugs Act lists cannabinol derivatives in Class B without naming THCV, and one 2025 paper calls THCV a UK controlled cannabinoid. This is not legal advice.

^{35 3 34 11}

Explore by health goal

Mental Wellbeing Brain Health Weight Management Blood Sugar Balance Metabolic Health Healthy Appetite Mobility Support Pain Relief Inflammation Balance Anxiety Support

Editorial transparency

Written by: AlternativeMed editorial team. Research compiled with AI assistance, then checked against PubMed records.
Medical review: None. This page has not been reviewed by a physician or pharmacist.
First published: 2026-10-25
Last substantive update: 2026-10-25
How we research: We searched PubMed and read the abstracts of the studies cited, read the FDA cannabis questions-and-answers page, a Congressional Research Service summary of the new US hemp definition and the UK Misuse of Drugs Act schedule, and read the full text of two open-access papers. Compound identity was checked in PubChem. Lab numbers come from a table of published data and are not our own testing.
How we rate evidence: See "How we rate evidence" in the Evidence tab.
Independence: No product is promoted on this page. No affiliate links are shown, and none will be added for THCV. This page is information, not a recommendation to use any product.

Sources 41

Each source was opened and checked. Where we read only the abstract, it says so. The small numbers in the text point here.

Bolognini D, Costa B, Maione S et al.. The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.. Br J Pharmacol. 2010. PMID 20590571. DOI 10.1111/j.1476-5381.2010.00756.x. (abstract)
Cammà G, Verdouw MP, van der Meer PB et al.. Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.. Eur Neuropsychopharmacol. 2025. PMID 39541799. DOI 10.1016/j.euroneuro.2024.10.006. (abstract)
Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (CRS In Focus IF13136), updated September 28, 2026. CRS In Focus. 2026. (full-text)
Deiana S, Watanabe A, Yamasaki Y et al.. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.. Psychopharmacology (Berl). 2012. PMID 21796370. DOI 10.1007/s00213-011-2415-0. (abstract)
ElSohly MA, deWit H, Wachtel SR et al.. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.. J Anal Toxicol. 2001. PMID 11599601. DOI 10.1093/jat/25.7.565. (abstract)
Englund A, Atakan Z, Kralj A et al.. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.. J Psychopharmacol. 2016. PMID 26577065. DOI 10.1177/0269881115615104. (abstract)
Espadas I, Keifman E, Palomo-Garo C et al.. Beneficial effects of the phytocannabinoid Δ(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.. Neurobiol Dis. 2020. PMID 32387338. DOI 10.1016/j.nbd.2020.104892. (abstract)
García C, Palomo-Garo C, García-Arencibia M et al.. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.. Br J Pharmacol. 2011. PMID 21323909. DOI 10.1111/j.1476-5381.2011.01278.x. (abstract)
Gojani EG, Wang B, Li DP et al.. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.. Molecules. 2023. PMID 37764262. DOI 10.3390/molecules28186487. (abstract)
Haghdoost M, Peters EN, Roberts M et al.. Tetrahydrocannabivarin is Not Tetrahydrocannabinol.. Cannabis Cannabinoid Res. 2025. PMID 38995871. DOI 10.1089/can.2024.0051. (full-text)
Hambidge T, Nash R, Corless S et al.. Validated LC-MS/MS methodology for the quantification of CBD, trace level THCA and UK controlled cannabinoids (Δ(9)-THC, Δ(8)-THC, CBN and THCV) in food samples.. Anal Methods. 2025. PMID 39832132. DOI 10.1039/d4ay01946f. (abstract)
Hill AJ, Weston SE, Jones NA et al.. Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats.. Epilepsia. 2010. PMID 20196794. DOI 10.1111/j.1528-1167.2010.02523.x. (abstract)
Jadoon KA, Ratcliffe SH, Barrett DA et al.. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.. Diabetes Care. 2016. PMID 27573936. DOI 10.2337/dc16-0650. (abstract)
Johnson E, Kilgore M, Nuzzo P et al.. Minor Cannabinoid Profile of Unregulated Cannabidiol Products.. Cannabis Cannabinoid Res. 2025. PMID 39478329. DOI 10.1089/can.2024.0058. (abstract)
Kayir H, Kouroukis L, Aziz I et al.. Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.. Biomolecules. 2025. PMID 41008636. DOI 10.3390/biom15091329. (abstract)
Kulpa J, Henderson RG, Schwotzer D et al.. Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats.. Cannabis Cannabinoid Res. 2023. PMID 37721989. DOI 10.1089/can.2023.0049. (abstract)
Levin FR, Mariani JJ, Brooks DJ et al.. Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol.. Drug Alcohol Depend. 2010. PMID 19733018. DOI 10.1016/j.drugalcdep.2009.07.021. (abstract)
LoParco CR, Bone C, Garg A et al.. Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.. J Psychoactive Drugs. 2025. PMID 40131178. DOI 10.1080/02791072.2025.2484376. (abstract)
McPartland JM, Duncan M, Di Marzo V et al.. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.. Br J Pharmacol. 2015. PMID 25257544. DOI 10.1111/bph.12944. (abstract)
Mendoza S. The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.. AIMS Neurosci. 2025. PMID 40270953. DOI 10.3934/Neuroscience.2025003. (abstract)
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.. Br J Pharmacol. 2008. PMID 17828291. DOI 10.1038/sj.bjp.0707442. (abstract)
Peters EN, MacNair L, Harrison A et al.. A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ(8)-Tetrahydrocannabivarin in Healthy Participants.. Cannabis Cannabinoid Res. 2023. PMID 37721990. DOI 10.1089/can.2023.0038. (abstract)
Poceviciute I, Simkunaite-Rizgeliene R, Mlost J et al.. Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain.. Sci Rep. 2026. PMID 42151379. DOI 10.1038/s41598-026-51275-7. (abstract)
Poceviciute I, Arbaciauskas M, Buisas R et al.. Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.. Alcohol Alcohol. 2026. PMID 41947574. DOI 10.1093/alcalc/agag019. (abstract)
Rao Q, Zhang T, Pu QL et al.. Comparative metabolism of THCA and THCV using UHPLC-Q-Exactive Orbitrap-MS.. Xenobiotica. 2023. PMID 36951512. DOI 10.1080/00498254.2023.2194981. (abstract)
Riedel G, Fadda P, McKillop-Smith S et al.. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.. Br J Pharmacol. 2009. PMID 19378378. DOI 10.1111/j.1476-5381.2008.00107.x. (abstract)
Rzepa E, Tudge L, McCabe C. The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers.. Int J Neuropsychopharmacol. 2015. PMID 26362774. DOI 10.1093/ijnp/pyv092. (abstract)
Sempio C, Campos-Palomino J, Klawitter J et al.. Pharmacokinetics of Oral Cannabinoid Δ8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants.. Pharmaceuticals (Basel). 2024. PMID 39770444. DOI 10.3390/ph17121603. (full-text)
Sempio C, Campos-Palomino J, Klawitter J et al.. Metabolite patterns in human urine after oral administration of highly purified Δ8-THCV.. Forensic Toxicol. 2026. PMID 42250012. DOI 10.1007/s11419-026-00772-5. (abstract)
Shirakura S, Ohta A, Abe H et al.. Emerging cannabinoids differ in behavioral safety margins in mice: a comparative hazard proximity analysis of locomotor suppression and catalepsy-like immobility.. Forensic Toxicol. 2026. PMID 42734683. DOI 10.1007/s11419-026-00786-z. (abstract)
Smith GL. Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips.. Cannabis. 2025. PMID 39968488. DOI 10.26828/cannabis/2024/000206. (abstract)
Stone NL, Murphy AJ, England TJ et al.. A systematic review of minor phytocannabinoids with promising neuroprotective potential.. Br J Pharmacol. 2020. PMID 32608035. DOI 10.1111/bph.15185. (abstract)
Tudge L, Williams C, Cowen PJ et al.. Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.. Int J Neuropsychopharmacol. 2014. PMID 25542687. DOI 10.1093/ijnp/pyu094. (abstract)
UK Parliament / legislation.gov.uk. Misuse of Drugs Act 1971, Schedule 2 (legislation.gov.uk). legislation.gov.uk. 2026. (full-text)
US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Questions and Answers. FDA website. 2024. (full-text)
US National Library of Medicine. PubChem compound record: Tetrahydrocannabinol (CID 16078). PubChem. 2026. (full-text)
US National Library of Medicine. PubChem compound record: Tetrahydrocannabivarinic acid (CID 59444416). PubChem. 2026. (full-text)
US National Library of Medicine. PubChem compound record: Cannabidivarin (CID 11601669). PubChem. 2026. (full-text)
US National Library of Medicine. PubChem compound record: Tetrahydrocannabivarin (CID 93147). PubChem. 2026. (full-text)
Wargent ET, Zaibi MS, Silvestri C et al.. The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.. Nutr Diabetes. 2013. PMID 23712280. DOI 10.1038/nutd.2013.9. (abstract)
Wiley JL, Marusich JA, Blough BE et al.. Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.. Prog Neuropsychopharmacol Biol Psychiatry. 2024. PMID 38417478. DOI 10.1016/j.pnpbp.2024.110984. (abstract)

Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.